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TECHNOLOGIES FOR PROTEOMIC AND GENOMIC BIOMARKER
ANALYSIS
YIDING LIU
ABSTRACT
In the first part of this dissertation, we systematically validated the application of
molecular

weight

cut-off

ultrafiltration

in

separation

and

enrichment

of

low-molecular-weight peptides from human serum. Under optimized conditions, both
free-phase and bound LMW peptides could be separated and enriched. The method
proved to be highly efficient and reproducible coupled with MALDI-TOF MS proteomic
pattern analysis. Three marker peaks were found to be eligible for distinguishing normal
and ovarian cancer samples.
A novel organic solvent precipitation method coupled with enzymatic
deglycosylation was also developed for biomarker detection from human serum. This
method allowed us to generate reproducible free-phase peptide patterns comparing with
the ultrafiltration method. A potential marker was found up-regulated in benign and
ovarian cancer patients. It was further identified as des-alanine-fibrinopeptide A using LC
tandem mass spectrometry.
In the second part of this dissertation, a new sample preparation procedure was
developed to improve the MALDI-TOF analysis of low-concentration oligonucleotides.
The oligonucleotide solutions are first dispensed and allow shrinking onto a small spot on
an anchoring target. A small volume (0.1uL) of saturated 3-HPA matrix solution is then
iii

added on top of each dried oligonucleotide spot. Samples prepared by this procedure are
homogenous and reduces the need to search for ‘sweet’ spots. The increased shot-to-shot
and sample-to-sample reproducibility makes it useful for high-throughput quantitative
analysis. This procedure allowed robust detection of oligonucleotides at 0.01µM level and
mini-sequencing products produced using only 50 fmol of extension primer.
And a strategy called probe-clamping-primer-extension-PCR (PCPE-PCR) was
developed to detect MRS alterations in a large background of wild-type DNA. PCR
errors often generate false positive mutant alleles. In PCPE-PCR, mutant single-strand
DNA molecules are preferentially produced and enriched. Thereafter, the remaining
single-strand mutant DNA molecules were amplified using PCR and analyzed to reveal
the MSI-H status. We showed that PCPE-PCR could detect both mutated BAT26 and
TGF-h-RII(A)10 markers in the presence of 500-fold excess of normal DNA and that as
few as three copies of mutated DNA could be detected. We also showed that this
technology could detect MSI-H colorectal cancer by fecal DNA analysis.
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PART I
TECHNOLOGY DEVELOPMENT FOR PROTEOMIC BIOMARKER
ANALYSIS

1

CHAPTER I
GENERAL INTRODUCTION

1.1 Proteomics Basics
After the human genome sequence was determined in 2000, molecular
medicine research moved further beyond genomics to proteomics.
What is proteomics? Although the exact definition of proteomics evolves
along with research progress [Wasinger et al., 1995; Loo et al., 1996; Wilkins et al.,
1996; Hochstrasser, 1998], it is widely accepted now that proteomics is “the study of
all the protein forms expressed within an organism as a function of time, age, state,
external factors, etc.” [Reynolds, 2002]. In other words, the types of expressed
proteins, their abundance, state of modification, sub-cellular location, etc. are
dependent on the physiological state of the cell or tissue. Therefore, proteomic
analysis can be considered as an assay surveying throughout the whole genome to
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differentiate and study cellular states and to determine the molecular mechanisms
behind them [Haynes et al., 1998].
Why proteomics? After the Human Genome Project was completed,
researchers noted that the genomic information itself can not accurately predict what
is actually occurring at the protein level within a certain cell type. The expression of
genes in a specific cell is affected by numerous factors as a result of tissue complexity,
inter- or intracellular signaling and responding to changes in their environment. Since
proteins are the working units to perform functions of a cell, and since their
expression, structure, and activity can be changed any time through post translational
modifications, proteomics, a new paradigm comparable to genomics, is therefore
needed. Proteomics provided a powerful approach for differentiating normal and
transformed cell formations, identification of molecular targets from complex
mixtures which are specific to disease, evaluating protein-based drug targets with
novel endpoints for better treatment of various malignant diseases [Verma et al.,
2001].

1.2 Cancer Detection and Molecular Biomarkers
Cancer remains to be a major challenge to public health despite progress in
detection and therapy. A large portion of the US population will develop cancer during
their lifetime [Chaurand et al., 2001], with ~50,000 individuals dying annually from
the disease [American Cancer Society, 1996]. With the better understanding of
molecular basis of malignant diseases, cancer diagnosis and treatment has become
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more target-oriented but still limited in the late invasive and metastatic stages. This in
turn greatly limited the success of treatment. It is generally accepted that if molecular
targets in the earliest stage of tumor growth can be identified, the treatment of cancer
is likely to be more effective and successful [Negm et al., 2002].
Molecular markers are defined as detectable species that are characteristic in
case of an organism’s state of health or disease, or are responsive to a particular
clinical treatment [Negm et al., 2002]. It is known that changes in molecular levels
occur at the beginning of the tumor growth. To detect these changes, diagnostic assays
using molecular biomarkers have considerable potentials for early cancer detection.
Proteomics, especially serum proteomics, is unquestionably valuable in the
discovery of biomarkers. Proteomes could reflect both the genetic coding of the cell
and the impact of their surrounding microenvironment. Due to altered expression,
posttranslational modification and other intra- or inter-cellular events, distinguishable
changes will occur at the protein level during the transformation of healthy cells into
cancer cells [Banks et al., 2000]. Therefore, the ability to make accurate measurement
about the state of pathology (or health) within organ systems by analyzing the fluid
that perfuses them, especially as in serum/plasma, has several major advantages.
Firstly, for a biomarker (or set of biomarkers) to be clinically valuable, it must be
disease-specific and be accurately detected. To some extent, components found in the
serum represent the cumulative effect of disease processes in organ tissue, and some
of those were not recognized by previous clinical practices. This makes serum a
valuable source of molecular biomarkers with high expected specificity. And
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moreover, because traces of the molecular footprints of on-going disease process are
expected to equilibrate in the circulation system, the strong possibility of sampling
error that is often associated with tissue biopsy is reduced substantially. Secondly, to
be applicable for clinical uses, any source of biomarkers must be readily obtainable
from the patient. Serum or plasma is one of the best sources for biomarker discovery
and screening because phlebotomy can be repeated as often as needed. Therefore,
serum investigations provide relative ease of sampling compared with the biopsy of
solid organs.
There are several clinical cases where molecular markers from serum are
already being used. For example, increased serum levels of prostate-specific antigen
(PSA) and cancer antigen-125 (CA-125) are routinely used for the detection of cancer
in the prostate and ovary, respectively [Grossklaus et al., 2002; Guppy et al., 2002].
However, there are no molecular markers clinically available for most types of cancer
in terms of early stage diagnosis, especially for several most deadly cancers such as
lung cancer and breast cancer.

1.3 Technologies Involved in Cancer Proteomic Research:
1.3.1 Two-Dimensional Gel Electrophoresis
Two-dimensional gel electrophoresis (2D-GE) has been the mainstay of
electrophoretic technology for a decade and is one of the most widely used tools for
separating proteins. In 2D-GE, proteins are first separated by isoelectric focusing (IEF)
based on the charge state of proteins and then further resolved by sodium dodecyl
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sulfate polyacrylamide gel electrophoresis (SDS–PAGE) in a second, perpendicular
dimension according to their size. Separated proteins can then be visualized by all
kinds of staining methods (Coomassie Blue and Silver stain, for example), or by
autoradiography, producing a two-dimensional image that contains thousands of
proteins [Klose et al., 1995]. The identification of proteins in each stained spot could
be achieved using immunoblotting, N-terminal sequencing or tandem mass
spectrometry [Hunter et al., 2002]. In many applications, 2D-GE was used to evaluate
cell lysates, tissue, or biofluid protein extracts [Jiang et al., 2003; An et al., 2004;
Vitorino et al., 2004]. The commercialized use of narrow, immobilized PH gradients
for the first dimension can increase resolving power and help detect low-abundance
proteins [Görg et al., 2000]. Differences between the samples can be compared and
relative quantities determined by quantifying the spot intensity ratios in different 2D
gels.

Matrix-assisted

desorption/ionization

time-of-flight

mass

spectrometry

(MALDI-TOF MS) and high resolution LC tandem mass spectrometry allow the
identification and quantification of very small amounts of protein isolated from the
gel. During last several years, increasing numbers of researches in cancer biomarker
screening and discovery were reported using 2D differential gel electrophoresis
(2D-DIGE, see Figure 1.1) coupled with mass-spectrometry [Arthur et al., 2002;
Schulenberg et al., 2003; Friedman et al., 2004].
However, in spite of all these achievements made in the past decade, 2D-GE
still suffers from several major limitations. These limitations includes: requirement of
relatively large sample quantities (the limit for the detection of proteins with silver
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staining is approximately 1 ng, i.e., 20 fmol for a 50 kDa protein [Shevchenko et al.,
1996], difficulties in detecting proteins with extreme molecular mass (large or small)
and isoelectric point, limited dynamic range according to staining method used, poor
reproducibility, labor intensive and difficulties in automating [Beranova-Giorgianni,
2003].
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Figure 1.1 Schematic illustration of the difference gel electrophoresis (DIGE)
technology platform [“Detection technologies in proteome analysis”, Wayne F. Patton,
2002]. Two different samples are derivatized with two different fluorophores,
combined and then run on a single 2D gel. Proteins are detected using a dual laser
scanning device or xenon arc-based instrument equipped with different excitation
/emission filters in order to generate two separate images. Differences in protein
expression are identified by evaluation of a pseudo-colored image and data
spreadsheet. DIGE technology can maximally evaluate three different samples using
Cy2-, Cy3- and Cy5-based chemistries.
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1.3.2 Multidimensional Protein Identification Technology
Multidimensional protein identification technology (MudPIT) is a method
that couples a microscale two-dimensional chromatography system to a tandem mass
spectrometer, which allows high-throughput analysis of a complex proteome (see
Figure 1.2). First introduced by A. J. Link and colleagues, strong cation exchange
(SCX) resin is placed upstream of the RP portion of the HPLC column [Link et al.,
1999], forming a in-line 2D HPLC separation system.
Peptides are bound to the SCX phase first under acidic/low-salt environment
and subsequently eluted off using multiple high salt pulses with higher PH buffers,
followed by reversed phase separation of each subset of peptides. For analysis of even
more complex protein mixtures, such as whole cell extracts and serum/plasma, greater
separation and data acquisition capacity is required. Further optimizations in
combinations of various HPLC methods, buffers, and even enhancement of general
strategy have resulted in a much more advanced MudPIT [Washburn et al., 2001;
Wolters et al., 2001]. All kinds of multidimensional chromatography coupled with
tandem mass spectrometry have been developed recently. With the high efficiency
micro capillary LC-MS or even nanoscale LC-MS, a lot of achievements have been
reported in cell or serum/plasma proteome research [Chen et al., 2002; Wagner et al.,
2003; Chen et al., 2004]. Hundreds of proteins, including ~pg/ml low abundance
(angiotensinogen precursor, cytokins, interleukin) proteins, can be detected and
identified [Tirumalai et al., 2003]. Although mixed-bed packing in one HPLC column
was a patented setup for the original MudPIT technology, the idea of
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multi-dimensional separation coupled with MS/MS detection was well adapted for
analyzing highly complicated proteomes. This strategy has played a very important
role on proteomic biomarker discovery.

1.3.3 Isotope-coded Affinity Tag
The prototypical method to generate quantitative protein profiles based on
stable isotope affinity tagging and MS is the isotope-coded affinity tag (ICAT) reagent
method [Gygi et al., 1999]. The first generation reagents (see Figure 1.3) consist of a
cysteine-reactive group, a linker that contains either heavy or light isotopes, and a
biotin affinity tag.
In ICAT reagent method (see Figure 1.4), two protein extracts representing
different cell states (i.e. healthy and diseased) are treated with the isotopically light or
heavy ICAT reagents, respectively. In this labeling step, ICAT reagents are covalently
attached with cysteine residues. The labeled protein mixtures are then combined and
digested using enzyme of choices (usually by trypsin). ICAT labeled peptides which
contain

cysteine

residue(s)

could

be

selectively

isolated

using

affinity

chromatography and analyzed by mass spectrometry. The relative abundance is
determined by the ratio of signal intensities of the tagged peptide pairs. The MS/MS
spectra are recorded and searched against protein sequence databases to identify the
protein. Therefore, in a single operation, the relative abundance and sequence of a
peptide can be determined [Tao et al., 2003].
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Figure 1.2 The online MudPIT interface developed by Yates and colleagues [“Direct
analysis of protein complexes using mass spectrometry”, A. J. Link et al., 1999]. It
includes biphasic microcapillary column, packed with strong cation-exchange (SCX)
and reversed-phase (RP) packing material connected to a microcross. The microcross
splits the flow from the HPLC column to 0.15-0.25 uL/min and serves as the
connection for the electrospray voltage.
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Cysteine residues represent a good target to reduce the complexity of digests
from large proteomes or other complex protein samples. This is because 96.1% of all
human proteins are known to have cysteine residue(s) but only 26.6% of the peptides
contain cysteine after tryptic digestion [Zhang et al., 2003]. Furthermore, there are
other chemical methods available to target the SH group on the side chain of reduced
cysteine [Zhou et al., 2002]. Therefore, cysteine becomes one of the most useful
targets for residue-specific enrichment. And the isotope-coded affinity tag (ICAT)
method has become widely used for quantitative proteome profiling.
The second generation of ICAT reagent contains an acid-cleavable linker
within the ICAT reagent molecule. This allows removal of the biotin affinity tag
before MS and MS/MS analysis. The improved MS/MS performance will
significantly increases the number of proteins identified in a single experiment and
quantify them with higher confidence scores. Incorporation of

13

C rather than

deuterium into the ICAT heavy reagent molecule overcomes isotope-co-elution effect
in reversed phase chromatography, thereby increases the accuracy of quantification
measurements using LC-MS. Recently, Kubota et al. reported proteome analysis of
secreted proteins during osteoclast differentiation using ICAT, together with 2D-GE
and 2D LC-MS [Kubota et al., 2003]. Meehan et al. reported quantitative profiling of
LNCaP prostate cancer cells using ICAT and mass spectrometry [Meehan et al.,
2004].

12

Figure 1.3 The structure of ICAT reagents [“Advances in quantitative proteomics via
stable isotope tagging and mass spectrometry”,W Andy Tao and Ruedi Aebersold,
2003]. ICAT reagents comprise a cysteine-reactive group, a linker containing either
heavy or light isotopes and a binding affinity tag.

Figure 1.4 The ICAT reagent strategy of quantifying differential proteins [“Advances
in quantitative proteomics via stable isotope tagging and mass spectrometry”,W Andy
Tao and Ruedi Aebersold, 2003].
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A more recent study conducted by Molloy and colleagues pointed out an
issue that using ICAT-MS technology tends to under represent low molecular weight
basic proteins in the proteome [Molloy et al., 2005]. Their research also indicates that
ICAT-MS technology was not much superior than 2-DE coupled with MS on
detecting highly hydrophobic transmembrane proteins. This will surely limit the
application of ICAT-MS technology in these disciplines.
All in all, ICAT MS technology provided

essential

quantitative

reproducibility and sensitivity for general proteomic analysis.

1.3.4 SELDI and Proteomic Pattern Analysis
Surface-enhanced laser desorption/ionization time of flight MS (SELDI-TOF)
is a novel approach introduced by Hutchens and Yip [Hutchens et al., 1993]. It
combines various retention surfaces with MALDI mass spectrometry. Samples are
captured by adsorption, partition, electrostatic interaction, or affinity chromatography
on a solid-phase protein chip surface (see Figure 1.5) before MALDI-TOF MS
analysis.
Liotta and Petricoin’s group pioneered the use of SELDI-TOF MS for the
detection of prostate and ovarian cancer based on proteomic pattern diagnostic
approach [Petricoin III et al., 2002a,b]. It is suggested that this approach can
successfully distinguish protein counterparts that differ by expression level, providing
a fingerprint map of proteomic contents within different specimens. Its core
hypothesis is that proteins or protein fragments produced by neoplastic cells may
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eventually enter the blood circulation system. The abundance of these
proteins/fragments could be analyzed directly with SELDI-TOF MS. A well designed
mathematical algorithm is a must for data interpretation and the extracted infomation
could be used for diagnostic applications. In addition to the original FDA group’s
results, other groups also reported biomarker analysis of prostate cancer using
SELDI-TOF proteomic pattern approach [Adam et al., 2002; Qu. Y et al., 2002;
Banez et al., 2003; Lehrer et al., 2003]. A similar approach has also been utilized in a
study on ovarian cancer [Kozak et al., 2003]. Metal affinity (IMAC-Cu), hydrophobic
(C16 or H4) or weak cation exchange (WCX2) chips were used in these researches. In
general, it has been suggested that this technology can achieve much higher
diagnostic sensitivity and specificity (approaching 100%) in comparison to the
classical cancer biomarkers.
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Figure 1.5 The arrays consist of either 8 or 16 spots composed of a specific
chromatographic surface [“Current developments in SELDI affinity technology”,
Ning Tang et al., 2004].
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1.4 Issues Associated With Current Human Serum/Plasma Proteome Research
and Our Strategy
1.4.1 Dynamic Range Issue
The concentration range of serum/plasma proteome is one of the major
challenges in cancer marker detection. Among the high abundance group, serum
albumin has a concentration of about 35-50mg/mL. At the low abundance end,
interleukin 6 has a normal concentration range between 0-5pg/ml [Anderson et al.,
2002]. This extraordinary high dynamic range (106~109) exceeds most of the
contemporary analytical methods, including high efficiency micro capillary LC-MS.
Therefore, when targeting low abundance biomarkers, proper fractionation of proteins
prior to the final detection and identification is a must for serum/plasma proteome
researches. It has been reported that removal of serum albumin and immunoglobulins
using affinity chromatography could enhance the detection of low molecular
weight/low abundance proteins [Sato et al., 2002; Adkins et al., 2002]. However,
those major protein components, especially albumin, in serum are well known to be
carrier or transporter of other smaller proteins [Curry et al., 2002]. Therefore, many
important low-molecular-weight (LMW) proteins/peptides could have been removed
by affinity depletion process. R. S. Tirumalai and colleagues reported an ultrafiltration
approach to deplete high abundance proteins and thus to enrich LMW portion of
serum proteome [Tirumalai et al., 2003]. With 341 proteins identified, including very
low abundance interlukins, their result is pretty attractive. However, among all the
proteins identified, the recovery rate of LMW proteins was only 15-20%, and most
(83%) of proteins were identified by only 1 unique peptide.
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1.4.2 Quantification/Data Interpretation Issue
The SELDI based approach is simple, can be high-throughput, and could be
easily automated. However, despite the reported success on detecting cancer from
serum, the SELDI based approach using affinity protein chip has several intrinsic
limitations, which may compromise the clinical use of this approach.
The most serious issue encountered is its poor reproducibility. In fact, the
findings from one lab are essentially not repeatable by others [See Table 1.1]. For
example, the SELDI approach has been used by several groups to detect prostate
cancer [Adam et al., 2002; Petricoin III et al., 2002; Qu. Y et al., 2002; Banez et al.,
2003; Lehrer et al., 2003]. Adam et al. found nine peaks, while Petricoin used 7 peaks
to differentiate cancer from noncancer. Interestingly, none of the peaks were identical.
Qu et al. who originally belonged to Adam’s group conducted the research using the
same chip and the same instrument. A comparison of the results from these two
groups yielded different sets of diagnostic peaks (in fact, only two peaks were
identical). In addition, although Adam et al. identified a peak as a marker
distinguishing between cancer and noncancer, the same peak was used by Qu et al. to
distinguish a healthy individual from a patient with benign hyperplasia.
The reproducibility issue is believed to be caused by nonspecific interaction
and saturation of protein chip surface with high abundance interfering proteins in a
random manner. Without proper fractionation, analyzing serum samples directly on
SELDI chips will not be able to overcome this obstacle.
Reproducibility could be somewhat improved by the use of better algorithms
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[Alexe et al., 2004; Petricoin et al., 2004]. It is also suggested that better
quality-control and quality-assurance are critical for reducing variability and potential
bias [Wulfkuhle et al., 2003; Petricoin et al., 2004]. However, what has been
overlooked thus far is the non-quantitative and non-reproducible nature of the
currently used SELDI-based serum proteomic pattern approach itself. The proteomic
pattern analysis requires at least a semi-quantitative comparison of the relative
intensity of a marker peak in both control and disease samples. Nevertheless, both
direct serum protein extraction on chip and the following MALDI detection used in
the SELDI approach are often biased and not quantitative, thus leading to poor
reproducibility.
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a. This table is from “Mass Spectrometry as a Diagnostic and a Cancer Biomarker
Discovery Tool: Opportunities and Potential Limitations”[Eleftherios P.
Diamandis, 2004].
b. M/Z ratios were rounded to whole numbers for simplicity. M/Z ratios in bold font
represent those identified by Adam et al. and Qu et al. for differentiating cancer
from non-cancer patients. The underlined M/Z ratio represents a peak identified
by Adam et al. for differentiating cancer from non-cancer patients and by Qu et al.
for differentiating healthy individuals from patients with benign prostatic hyper
plasia.
c. BPH, benign prostatic hyperplasia.
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The goal of the first part of my dissertation is to develop a multidimensional
fractionation strategy involving molecular weight cut-off (MWCO) ultrafiltration
and/or other separation methods which can deplete high abundance proteins as well as
retain and enrich low molecular weight (LMW) or low abundance proteins/peptides.
Instead of struggling on perfect molecular weight cut-off, we will focus on efficient
and quantitative recovery of targeted sub-proteome from human serum samples.
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CHAPTER II
SEPARATION AND ENRICHMENT OF FREE-PHASE AND BOUND
LOW-MOLECULAR-WEIGHT FRACTION FROM HUMAN SERUM USING
ULTRAFILTRATION FOR MALDI-TOF-MS PATTERN ANALYSIS

2.1 Introduction
After completed the Human Genome Project, researchers started a new
journey exploring proteomes in various organism. Since proteins play a major role in
the molecular pathways that drive all kinds of cellular functions, the elucidation of
diseases’ mechanisms, such as cancer, requires further study and identification of
these proteins [Ashcroft, 2002]. It was widely accepted that early detection is critical
in cancer control and prevention. Proteomics study could help finding novel
biomarkers and pathological pathways for early detection and prognosis. One of the
major parts of cancer proteomics involves the identification of differentially expressed
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proteins and quantitative comparison of those proteins at various disease stages with
their counterparts in healthy specimen [Srinivas et al., 2001].
Matrix-assisted desorption/ionization time-of-flight mass spectrometry
(MALDI-TOF-MS) has been an important tool for proteomic research. Cell [Lee et al.,
2004], tissue [Pierre et al., 2001], cerebrospinal fluid [Davidsson et al., 1999], urine
[Lin et al., 2006], plasma/serum [Kiernan et al., 2004; Wang et al., 2003], virtually
any specimen that are commonly used for clinical research and disease diagnosis
could be analyzed using MALDI-TOF-MS.
Surface

enhanced

laser

desorption/ionization

time-of-flight

mass

spectrometry (SELDI-TOF-MS), a modified version of MALDI-TOF-MS, has also
been used to generate protein profiles directly from plasma/serum. Promising results
have been reported on ovarian cancer, prostate cancer, and lung cancer samples,
several candidate markers have been found [Petricoin et al., 2002; Kozak et al., 2003; Banez
et al., 2003; Zhukov et al., 2003].

However, using MALDI-TOF-MS to generate complete protein expression
profiles of these complex biological samples encountered some difficulties, and they
are either intrinsic from MALDI-TOF-MS, or directly derived from the complexity of
the sample themselves.
Serum, derived from plasma after clotting, contains 60-80mg/ml proteins.
The major protein constituents of serum include albumin, immunoglobulins,
transferrin, haptoglobin, and lipoproteins [Turner et al., 1970; Burtis et al., 2001]. In
addition to these major constituents, serum also contains many other proteins that are

23

synthesized and secreted, shed, or lost from cells and tissues throughout the body
[Wrotnowski, 1998; Kennedy, 2001]. It is estimated that up to 10,000 proteins may be
commonly present in serum [Wrotnowski, 1998]. This makes serum a perfect
reservoir of finding disease related biomarkers for various organs, including cancer.
However, there is one major limitation for using MALDI-TOF-MS in serum
proteomics. All species are not ionized equally. Species with higher abundance or
better ionization will tend to depress the signal of those with much lower relative
abundance. Therefore, with the presence of high abundance proteins in serum
(albumin, for example, 35-50mg/ml in serum), it will be impossible to detect those
low abundance proteins (e.g. C-reactive protein, osteoponin, and prostate-specific
antigen, which are below 10ng/ml in serum) using MALDI-TOF-MS.
One of the most widely adapted strategies for overcoming this dynamic range
issue is to remove high molecular weight proteins, enabling the detection of
remaining low molecular weight (LMW) proteins present in much lower
concentration. Various immuno-affinity columns have been developed for high
abundance protein depletion. Multiple affinity removal system (MARS) from Agilent
Technologies could effectively deplete 7 major interfering high-abundant proteins
(albumin, IgG, IgA, transferrin, haptoglobin, antitrypsin, and fibrinogen) from human
plasma samples, by which eliminates approximately 88-92% of total protein. Removal
of these abundant proteins improves the subsequent analysis of the serum sample by
effectively expanding the dynamic range of the analysis. However, it is well known
that HSA and immunoglobulins are functioning as carrier proteins in serum; many
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important low molecular weight peptides/proteins (e.g. hormones) bound to them
would be removed with their carrier proteins simultaneously [Zhou et al., 2004].
Because affinity methods used to deplete high abundance proteins under
non-denaturing conditions, this may result in the loss of potential disease-informative
LMW species.
Ultrafiltration, using molecular weight cut-off (MWCO) membrane, is
widely used to concentrate and purify macromolecules. Among these methods of
protein separation and fractionation, ultrafiltration is relatively simple, less expensive,
and can be used as a continuous process with high throughput at ambient temperature.
However, previous studies using ultrafiltration were not very successful. Georgiou
and colleagues [Georgiou et al., 2001] demonstrated that they had failed to completely
remove HSA and other high abundance proteins using centrifugal ultrafiltration. But it
was later pointed out by Tirumalai [Tirumalai et al., 2003] that using undiluted plasma
and centrifuging under high speed (12,000xg) may be the cause of their failure.
Triumalai and colleagues had compared the protein recovery under non-denaturing
(i.e., 25 mM NH4HCO3, pH 8.2) and denaturing conditions (i.e., 25 mM NH4HCO3,
pH 8.2 with 20% (v/v) acetonitrile). They found that the LMW fraction was
successfully enriched. Highly diluted serum and much slower centrifuge speed
(3000xg) were also proved to be effective for preventing HSA from leaking through
the filter membrane. They managed to identify 341 unique proteins from low
molecular fractions of serum using this improved procedure.
Here we demonstrated the separation and enrichment of free-phase and
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bound low molecular weight fraction in serum using MWCO ultrafiltration. Both
elution and denaturing conditions were optimized to achieve robust proteomic pattern
analysis using MALDI-TOF-MS and high quality protein identification using
LC-MS/MS. The result showed that under optimized conditions, ultrafiltration may
provide enough separation power to reproducibly elucidate potential biomarker
information from low molecular weight fraction of human serum.

2.2 Materials and Methods
2.2.1 Materials and Reagents
Milli-Q water was used for all solutions. Microcon® centrifugal filters (spin
column) with a molecular weight cut-off (MWCO) of 30kDa and ZipTip® C18
reversed phase pipette tips for sample preparation were purchased from Millopore
Corporation (Berford, MA). Phosphate-buffered saline (PBS) solution, trifluoroacetic
acid (TFA), HPLC grade acetonitrile, α-cyano-hydroxycinnamic acid (CHCA) were
purchased from BIO-RAD (Hercules CA), Pierce (Rockford, IL), Aldrich Chemicals
(Milwauke, WI), Bruker Daltonics (Billerica, MA), respectively.

2.2.2 Human Serum Resources and Information
Human serum from healthy donor was purchased from Sigma (St. Louis,
MO). Serum was thawed upon arrival and aliquot into smaller fractions to minimize
future freeze/thaw cycles. Most of method developments were done using this serum.
Serum from ovarian cancer patients and normal controls was obtained from GOG
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bank. Totally 20 ovarian cancer patient sample and 19 normal controls was used in
this study. These serum samples were also divided into smaller fractions upon
receiving and stored under -80 degree before further processing.

2.2.3 Centrifugal Serum Ultrafiltration
2.2.3.1 Free Phase Low Molecular Weight Fraction Collection
The centrifugal filter membrane in Microcon® spin columns were rinsed and
used according to the manufacturer’s instructions. 50µl serum was diluted with 250µl
PBS (pH 7.4), and gently mixed on a vortexer for 2 minutes. The sample was spun at
a speed of 14,000 rpm (~16,000xg on Eppendorf Centrifuge 5415C) for 10 minutes
before performing ultrafiltration to precipitate any insoluble particles that may clog
the membrane. The supernatant was then carefully pipetted into prepared centrifugal
filter. The sample was centrifuged (Eppendorf Centrifuge 5415C, Brinkman
Instruments, Westbury, NY, USA) at 5000 rpm for 30 minutes until about 90% of the
input serum solution had passed through the membrane, meanwhile, make sure there
was enough retentate left to avoid membrane dryness. An aliquot of 1xPBS solution
was then added into the sample reservoir to dilute the retentate to 300µl, and the
retentate was gently mixed by performing 10-15 aspirate-dispense cycles with pipette
tip before another consecutive centrifuge. Such operation was performed 8 times
totally. The filtrates in separate tubes were lyophilized to dry in Speed-Vac and
resuspended in 50µl of 0.1% TFA solution before MS analysis.
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2.2.3.2 Bound Low Molecular Weight Fraction Collection
After free-phase low molecular weight (LMW) fraction being eluted, the
retentate was collected by reversing the sample reservoir and centrifuging into a new
collection tube at proper lower speed according to the instruction manual. The total
volume of each retentate was about 30uL. It was then incubated with 100µl 8M urea
for at least 2 hours under ambient temperature. After that, the elution of bound LMW
fraction from denatured retentate was carried out in a new 30k MWCO spin column,
and all the eluting operations were the same as described in section 2.3.1.

2.2.4 MALDI-TOF-MS Pattern Analysis
2.2.4.1 Sample Preparation
ZipTip® C18 reversed phase pipette tips (Millopore, Billerica, MA) were used
for de-salting and concentrating of peptides/proteins prior to MALDI-TOF-MS
analysis. 10µl of the resuspended filtrates (free-phase or bound) were used for each
clean-up process. The elution buffer is 10ul 50% acetonenitrile with 0.1% TFA if not
otherwise mentioned. The reproducibility of this process was also tested using
MALDI-TOF-MS pattern analysis of resuspended filtrates from three separate
Microcon® spin columns.

2.2.4.2 MALDI-TOF-MS
Dried-droplet deposition of the sample was achieved by depositing 1µl (0.5µl
each time, apply the rest after the first drop dried) of sample solution onto stainless
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steel

MALDI

target,

and

then

overlaid

with

0.5µl

of

CHCA

(α-Cyano-4-Hydroxycinnamic Acid) matrix solution (5mg/ml in 50% acetonitrile,
0.1% TFA). For each sample, three duplicate spots were prepared to eliminate
possible fluctuations.
All mass spectra were collected using OminiFLexTM MALDI-TOF mass
spectrometer (Bruker, Bilerica, MA, USA) operated in the linear, positive mode with
delayed extraction turned on. OminiFLexTM MALDI-TOF mass spectrometer uses a
337nm pulsed nitrogen laser, which has a duration of 3ns and a full power of 175µJ.
MS spectra were collected in the range of 700-10000 m/z ratio. All experiments were
performed under 75% of full laser power with sampling rate of 5Hz if not otherwise
specified. 10 sampling points were randomly picked on each sample spot. One
hundred shots per sampling points were accumulated and all 10 sets of spectra were
combined to eliminate on-target fluctuation.

2.2.5 LC-MS/MS Analysis and Protein Identification
2.2.5.1 Trypsin Digestion
The collected LMW species were concentrated to 80μL/sample using
speed-vac and the PH of the solutions is adjusted to 7.8 using freshly made 100mM
NH4HCO3 if necessary. Trypsin digestion was conducted in solution using standard
procedure with some modifications. In general, there was no denaturation, reduction,
and alkylation before adding trypsin. The first dose of trypsin was added at a ratio of
1:100 (w/w) and incubated under 37℃ for 4 hours. The second dose of trypsin (1:50
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w/w) was added afterwards and incubated overnight under 37℃. Tryptical digests
were frozen under -20℃ before further analysis.

2.2.5.2 LC-MS/MS Analysis and Protein Identification
The LC-MS/MS analysis was performed on Agilent 1100 HPLC system
coupled in-line with a Bruker HCT 3000plus ESI-IonTrap Mass Spectrometer. 20μL
tryptic digested sample was injected and eluted from a Vydac C18 capillary RP-HPLC
column (10cm, 300µm ID) using the following gradient: 2% B, 10min; 5%-45% B,
200min; 45%-85% B, 30min; 85%B, 30min. Solvent A is 0.1% formic acid and 1%
acetonitrile in Milli-Q H2O, solvent B is 0.1% formic acid in acetonitrile.
Tendem MS data were merged into one single data file for both free-phase and bound
species. It was searched against NCBInr protein database using an in-house Mascot
server. The search was performed using no enzyme, trypsin, trypsin+chymotrypsin
separately and the results were combined. No taxonomy or modifications were
specified. Peptide mass tolerance is ±1.0Da, MS/MS tolerance is ±0.5Da, and
searched for all possible charge states (i.e. +1, +2, +3). The final result was manually
inspected to remove all false positives.

2.3 Results and Discussion
2.3.1 Centrifugal Ultrafiltration
Centrifugal ultrafiltration has long been used as clean-up/concentrating
method on bio-macromolecules such as DNA and proteins. The unique molecular
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weight cut-off membrane provided fast sample processing and high recovery rate.
However, when used on serum proteomics, especially for high-abundance protein
depletion, this method required special optimization.
Tirumalai [Tirumalai et. al., 2003] and Harper [Harper et al., 2004] had investigated
how experimental conditions, e.g. sample preparation, centrifugation time and speed,
sample size and protein concentration, would effect the result of centrifugal
ultrafiltration fractionation of serum. Some key factors had been pointed out but the
results were still far from satisfactory.
In our study, we introduced a systematic way of evaluating the performance
of centrifugal ultrafiltration in low molecular weight serum proteome studies. The
schematic demonstration of the strategy is shown in Figure 2.1.
In previous study [Tirumalai et. al., 2003], low molecular weight fractions
collected under non-denaturing and denaturing conditions were compared. As a
conclusion, much more proteins/peptides could be detected under denaturing
condition. Therefore denaturing conditions should be preferred and free-phase species
eluted under non-denaturing conditions was neglected. However, our study showed
that the amount of free-phase species could be much larger than people had thought
before.
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Figure 2.1 A schematic representation of separating and enriching free-phase and
bound peptides from serum using centrifugal ultrafiltration and MALDI-TOF pattern
analysis.
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In our study, serum sample was diluted with PBS to prevent denaturing
serum proteins, which minimized the disassociation of low molecular weight fraction
from major carrier proteins. A low centrifuge speed was also adapted from previous
studies to avoid protein leaking. Furthermore, we have found that only filtering once
was not sufficient enough to completely elute free peptide/proteins. A total of 8
consecutive ultrafiltrations under non-denaturing condition were performed to
maximally separate free-phase peptide/proteins. A SDS-PAGE analysis was
performed to demonstrate the effect of this process (See Figure 2.2).
According to the results in Figure 2.2, it was after 6 consecutive
non-denaturing ultrafiltrations when the amount of LMW proteins could be neglected.
During consecutive centrifuge process, the retentate was carefully resuspended by
gently performing aspirate-dispense cycles with pipette tip while not touching the
membrane, which could maximally avoid protein accumulation on the membrane and
pore clogging. The aspirate-dispense cycles made the solution be homogeneous
without concentration gradient, which resulted in uniform experimental conditions for
each ultrafiltration.
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Figure 2.2 SDS-PAGE analysis of free-phase and bound peptides in serum using
ultrafiltration with 30kDa cut-off spin column.
Lane 1: Molecular weight marker;
Lane 2 to Lane 5: Free-phase peptides, eluant 1 and 2, 3 and 4, 5 and 6, 7 and 8
combined respectively;
Lane 6 to 9: Bound peptides, eluant 1 and 2, 3 and 4, 5 and 6, 7 and 8 combined
respectively.
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The retentate part containing large carrier proteins was then incubated with
8M urea solution, resulting in the disruption of the protein/protein interaction and
separation of bound peptide/proteins from their carrier proteins. Thereafter, the
denatured retentate was filtrated with a new 30kDa molecular weight cut-off spin
column to collect the bound LMW species. PBS solution was used to dilute the
denatured protein solution and the elution of dissociated species. This could ensure
similar elution efficiency and minimize buffer effect during ultrafiltration procedure.
No gel-like precipitate or membrane clogging was observed during the ultrafiltration
of denatured proteins.
As could be seen in Figure 2.2, the amount of low molecular weight
proteins/peptides greatly increased after denaturing ultrafiltration. Moreover, most of
LMW fraction disassociated from their carrier proteins by denaturing also can be
completely eluted after 8 consecutive filtrations. And the components in free-phase
LMW fractions were dramatically different (smaller molecular weight) from those
eluted in bound fractions. The result clearly indicated the selective enrichment of both
free-phase and bound species. The reproducibility of this consecutive ultrafiltration
process was examined by MALDI-TOF MS pattern analysis using combined mixture
of 8 eluants for free-phase and bound peptides, respectively. The results were shown
in Figure 2.3.
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Figure 2.3 MALDI-TOF spectra obtained from the samples filtrated by three different
spincolumns.
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As indicated in MALDI-TOF MS pattern analysis, the free-phase peptides
demonstrated major difference from bound fraction. A side by side comparison
indicated that some major small molecular weight peaks in free-phase protein/peptide
samples disappeared or become weaker in bound peptide spectra, and many peaks
with larger M/Z ratio were much more abundant in bound protein/peptide spectra.
This is consistent with SDS-PAGE results. In summary, the ultrafiltration strategy we
developed can lead to both enrichment of LMW serum peptides and separation of
free-phase proteins/peptides from bound ones. Another important observation is that
the total quantity of the free-phase proteins/peptides is comparable to that of the
bound species in serum.
A series of test were carried out to verify that the increased quantity of
proteins after denaturation was neither yielded by the effect of membrane clogging
during centrifugal ultrafiltration (free-phase proteins/peptides leftover on membrane),
nor by the solvent elution efficiency difference between PBS and 8M urea.
Firstly, the retentate containing high molecular weight carrier proteins was
collected by placing the sample reservoir of Microcon spin column upside down, and
spun at a proper low speed according to the instruction manual. One part of collected
retentate was denatured and filtered in the same used Microcon spin column. Before
reusing, the used empty column was spun twice using PBS to remove possible
proteins/peptides leftovers on the membrane. In fact, no bands were observed for
collected filtrates on SDS-PAGE analysis (data not shown). And then the denatured
retentate was spun 8 times in washed used column using PBS as elution buffer. The
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other part of retentate was spun using used Microcon spin column directly without
washing. A third part of retentate was denatured and filtered using new clean
Microcon spin column, following procedure described before. MALDI-TOF MS
pattern analysis results were compared for these 3 differentially collected bound
peptide samples (see Figure 2.4A, B, C, respectively).
Secondly, the combined free-phase filtrates in PBS solution were also tested
in a similar manner, except one part was eluted directly with PBS for 8 times, the
other was incubated with 8M urea and then eluted 8 times with PBS. Both of them
were filtrated with using new spin columns. MALDI-TOF MS pattern analysis results
were also compared for these 2 differentially collected free-phase peptide samples in
Figure 2.4D and 2.4E.
As seen in Figure 2.4, with a slight difference of peak intensity, almost
identical proteomic patterns had been generated in each group of tests. Denatured
retentates generated completely deferent pattern from free-phase eluants. The patterns
are almost identical with their counterparts in Figure 2.3. These results suggested that
the decreasing quantity of free-phase peptides after multi-centrifugal ultrafiltration
and the increase in quantity of low molecular weight fraction after urea denaturation
were not resulted from membrane clogging or solvent effect. Separation of free-phase
LMW species, dissociation and enrichment of bound proteins/peptides from large
carrier proteins were achieved effectively using urea denaturatoin and centrifugal
ultrafiltration.
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Figure 2.4 Test of membrane clogging and solvent efficiency after 8 consecutive
ultrafiltration.
A. MALDI-TOF spectra of the re-centrifugal ultrafiltration of bound peptides from
serum, using used spin column without additional wash.
B. MALDI-TOF spectra of the re-centrifugal ultrafiltration of bound peptides from
serum, using used spin column after additional wash.
C. MALDI-TOF spectra of the re-centrifugal ultrafiltration of bound peptides from
serum, using new spin column.
D. MALDI-TOF spectra of the re-centrifugal ultrafiltration of free-phase peptides
from serum, eluted after 8M urea incubation.
E. MALDI-TOF spectra of the re-centrifugal ultrafiltration of free-phase peptides
from serum, eluted directly with PBS solution.
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2.3.2 MALDI-TOF Pattern Analysis - Method Development
MALDI-TOF pattern analysis was introduced in human serum proteomic
research by Patricoin and Liotta [Petricoin III et al., J. Natl. Cancer Inst. 2002, Lancet
2002]. Although the original SELDI approach resulted in debatable data [Diamandis,
2004], the idea of using differential comparison of healthy and patient proteomic
patterns for biomarker discovery is still a widely accepted strategy.
We developed a data acquisition procedure to robustly generate easy to read
proteomic patterns using MALDI-TOF MS. Every pattern was a combined spectrum
from 10 randomly selected sampling spots with 100 shots per spot for each sample
deposited on target. This would reduce spot to spot variation during sample
preparation in MALDI-TOF MS (known as “hot-spot effect”).
One set of MALDI-TOF MS spectra were collected from three MALDI
samples deposited on target using the same eluted LMW proteins/peptides. It was
seen that with the averaging effect, both the proteomic pattern and the relative
intensity of peaks were highly reproducible. And all combined spectra had shown
strong signal intensity with high resolution (data not shown). This made visual
identification of potential biomarker peaks a much easier job to do.

2.3.3 Protein Identification Using LC/MS/MS with Database Searching
Protein identification results using LC/MS/MS with database searching were
summarized in Table 2.1.
At first look, we identified less proteins compared with previous study. But
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our strategy has several advantages. Firstly, the data quality and the confidence level
of identification were much better than previous study. As mentioned before, our
8-cycle elution strategy could ensure complete collection of LMW species.
Enrichment of free-phase and bound peptides in two different step also could be
considered as an extra fractionation besides reversed-phase HPLC separation. Without
interferences from large high abundance proteins, the sensitivity of high resolution
mass spectrometry was further extended to detect low molecular weight fragments.
Secondly, since the strategies used in both studies were focused on low molecular
weight species in human serum, the number of LMW proteins detected should be an
important factor to evaluate the efficacy of the method. As indicated in table 1, our
method demonstrated much better result than previous study (90 LMW proteins
identified in our study v.s. 69 in previous study). Lastly, fragments from same protein
could be collected separately in both free-phase and bound fractions. So combining
MS/MS data before database searching could be one of the essential factors for
protein identification. Searching against non-tryptic fragmentation also could help
identify LMW species naturally present in serum.
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Table 2.1 Protein Identification Result Compared With
Previous Study [Tirumalai et al., 2003]
Previous
Study

Our Result

Total Proteins Identified

341

226

# of proteins Identified by only one unique
peptide

285 (83.5%)

36(16%)

# of proteins with predicted MW higher than
Cut-off MW (30kDa) of spin colum

282 (82.7%)

136 (60.2%)

# of proteins with predicted MW lower than
20k

38 (11%)

32 (14%)
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2.3.4 Biomarker Discovery Using MALDI-TOF Pattern Analysis
We were able to test our whole proteomic strategy on some clinical samples
obtained from GOG bank. A total of 39 serum samples were tested in our project.
There are 20 patient samples with ovarian cancer and 19 normal serum samples as
control set.
All experimental setup was the same as described above. MALDI-TOF
pattern

analysis

was

performed

for

free-phase

LMW

peptides,

free-phase-peptide-removed denatured LMW peptides and directly denatured LMW
peptides. All spectra were externally calibrated and normalized before bioinformatic
analysis.
Significant differences were found between cancer patient and normal control
when comparing free-phase peptide patterns. Same results were also found when
using directly denatured peptide patterns. Based on previous test results on centrifugal
ultrafiltration method, we could conclude that these differences were contributed
solely by free-phase peptides.
A typical pattern comparison was shown in Figure 2.5a. As could be seen,
three peaks were identified to differentiate cancer patients and normal control. To
further compensate for the intrinsic disadvantage of quantification using
MALDI-TOF MS, we used relative peak intensity ratio instead of peak intensity itself
to define cut-off thresholds. So there are 2 marker ratios used to distinguish cancer
and normal samples: M1/M2>1 and M1/M3>1. Both of them have to be satisfied for
positive classification of cancer. It could not be classified in either of the two groups if
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only one of them is satisfied.
Using these markers, 16 out of 20 cancer patients (80%) were correctly
identified. In the 4 misclassified samples, only 1 demonstrated a “normal” pattern
(M1/M2 and M1/M3 are all smaller than 1). We failed to detect any marker peaks in
the other 3 samples (as could be seen in Figure 2.5b).
Correct marker ratios (M1/M2<1 and M1/M3<1) were found in 79% of
normal samples. There were 2 samples that demonstrated false positive signals, and
the other 2 samples could not be classified in either group.
A t-test was also performed to verify the statistical significance of our results.
With an assigned p-value threshold as 0.05, marker ratio 1 (M1/M2) between two
sample groups has a p-value of 0.0009, and marker ratio 2 (M1/M3) is 0.04, all
indicating significant differences between patient and normal samples. Better results
could be obtained if we discard the 3 patient samples without any marker peaks
(M1/M2 p-value=0.0002 and M1/M3 p-value=0.025).
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Figure 2.5a. MALDI-TOF-MS pattern analysis of ovarian cancer patient serum and
normal serum.

Figure 2.5b. Software generated “virtual gel” indicating selected marker peaks in 2
sample sets.
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2.4 Conclusion
In this project, we evaluated a new application of centrifugal ultrafiltration in
human serum proteome study. Our results demonstrated successful separation and
enrichment of free-phase proteins/peptides and proteins/peptides bound to large
carrier proteins in serum.
Combining centrifugal ultrafiltration with MALDI-TOF MS pattern analysis,
we selected 3 marker peaks for differentiating ovarian cancer patients and healthy
controls. And we believe that these markers were found from free-phase fractions.
The sensitivity and specificity are 80% and 79%, respectively (using peak intensity
ratios). This is only a small pilot study with limited number of samples. More
validation should be done with larger sample sets using more standardized
procedures.
Based on the procedure we used in centrifugal ultrafiltration, a more accurate
definition for so called “free-phase” species should be “free and less tightly bound
molecules”, and this part of serum proteome was somehow ignored in previous
studies. Our results agreed with previous studies on the supreme complex nature of
serum proteome but provided new possibilities of finding potential biomarkers.
It will never be emphasized enough about the importance of removing high
abundance proteins before further study of the rest of serum proteome. However,
removal should not be the ending of these hard-working carriers. Each one of them
might represent a whole new sub-proteome and further thorough exploring may lead
to a world we never know.
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CHAPTER III
A NOVEL PROTEOMIC APPROACH USING ORGANIC SOLVENT
PRECIPITATION AND ENZYMATIC DEGLYCOSYLATION FOR
ELUCIDATING OVARIAN CANCER MARKERS IN HUMAN SERUM

3.1 Introduction
During the last decades, proteomics has been well accepted as a new
systematic tool of understanding various biological disorders. High sensitivity and
automated mass spectrometric techniques have been developed to enhance the
capability of analyzing highly complex biological samples.
However, there are still considerable limitations. When encountering whole
proteomes, the extraordinary dynamic range of protein components in a single cell, or
in plasma and serum has long been a huge obstacle before researchers. A 7-10 orders’
difference in concentration is surely out of the reach of any single contemporary
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proteomic techniques [Stasyk and Huber, 2004].
Pre-fractionation of the whole proteome before further analysis has been a
widely used strategy especially when focusing on biomarker discovery in low
molecular weight (LMW) fraction of human plasma/serum. Centrifugal ultrafiltration
has been used to separate and enrich the LMW serum proteome [Tirumalai et al.,
2003]. And it has also been used to demonstrate the complicated interactions between
serum proteins [Zhou et al., 2004]. Various immuno-affinity columns have been
developed to conveniently remove high abundance proteins from human serum
[Bjöhall et al., 2005], and a similar approach using affinity spin tube filter was also
shown to be effective [Wang et al., 2003].
However, there is one limitation associated with direct removal of large high
abundance proteins. In serum, dominating proteins such as albumin are known to be
carriers and transporters of proteins and other species [Schussler, 2000; Curry, 2002;
Dea et al., 2002]. Removal of LMW species spontaneously with their carriers may
greatly effect further identification and quantitative analysis. Therefore, disrupting
protein-protein interactions before removal of high abundance carrier proteins is an
essential step for LMW serum proteomic research. Tirumalai and Zhou demonstrated
that using centrifugal ultrafiltration under denaturing conditions could effectively
deplete high abundance large proteins as well as separate and enrich LMW proteins in
human serum; several new low abundance proteins in serum proteomic study has been
identified, too [Tirumalai et al., 2003; Zhou et al., 2004]. In our previous study (see
Chapter II), centrifugal ultrafiltration was used under optimized conditions to
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separate and enrich both free-phase and bound LMW species in human serum.
Furthermore, a series of potential markers were identified for distinguishing ovarian
cancer patients and normal controls using MALDI-TOF MS pattern analysis.
A novel approach using organic solvent extraction as a sample preparation method for
mass spectrometry based proteomic analysis has been reported recently [Chertov et al.,
2004]. They were using 50% acetonitrile solution with 0.1% trifluoroacetic acid as
denaturing reagent to extract LMW proteins/peptides from both turmor challenged
mice serum and normal human serum samples. The following surface enhanced laser
desorption/ionization (SELDI) TOF MS analysis identified several differentially
expressed protein markers. Compared with centrifugal ultrafiltration, organic solvent
precipitation is simple and effective on high abundance protein removal and LMW
protein enrichment.
In this study, we demonstrated an organic solvent precipitation approach on
detecting serum biomarkers for ovarian cancer. High concentration of acetonitrile
solution (80%) was used to improve high abundance protein depletion. An enzymatic
deglycosylation step was added before MALDI-TOF MS pattern analysis. It was
proved that for complex samples such as serum extract, deglycosylation could reduce
suppression effect and improve signal to noise ratio within low molecular weight
range. Biomarkers found from previous study were further evaluated and verified.
One of the major marker peaks was identified as des-alanine fibrinopeptide A and this
marker could be used to distinguish benign, carcinoma and non-cancer samples
successfully.

49

3.2. Methods and Materials
3.2.1 Materials
HPLC grade acetonenitrile was purchased from sigma (St. Louis, MO).
PNGase F (500 units/μL) was purchased from New England Biolabs (Ipswich, MA).
An aliquot of enzyme was diluted to 5units/μL immediately upon receiving with
supplied 1x G7 reaction buffer (50 mM sodium phosphate, pH 7.5) and stored at 4℃
until use. Microcon® centrifugal filters (spin column) with a molecular weight cutoff
(MWCO) of 30kDa and ZipTip® C18 reversed phase pipette tips were purchased from
Millopore Corporation (Berford, MA). Peptide calibration standard (1000~4000Da)
and ultra-pure α-CHCA (α-cyano-hydroxycinnamic acid) matrix were purchased from
Bruker Daltonics (Billerica, MA).

3.2.2 Serum Sample Information
Serum samples were obtained from multiple institutions. The first sample set
was obtained from Gynecologic Oncology Group tissue bank (18 normal, 20 patients).
All patients were diagnosed to have advanced stage ovarian cancer: 17 papillary
serous carcinomas, 1 endometrioid carcinoma, 1 clear cell carcinoma and 1 unknown
type.
The second sample set was obtained from Cooperative Human Tissue
Network – University of Pennsylvania Medical Center. There are 19 samples totally,
and they may have diseases other than cancer but no detailed information available.
One of them was from male donor and therefore excluded from our study.
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The third sample set was again obtained from Gynecologic Oncology Group
tissue bank (40 carcinomas and 20 benign). In cancer patient samples, there are 20
papillary serous carcinomas, 10 mucinous carcinomas, 5 endometrioid carcinomas
and 5 clear cell carcinomas. In samples from benign diseases, there are 10 serous
benign, 5 mucinous benign and 5 other benign.
All serum samples were aliquot to small fractions and stored under -80℃
before use.

3.2.3 Denaturation of Serum and Separation of LMW Species
40μL of serum was diluted and denatured in 2mL of 80% acetonenitrile in a
15mL centrifuge tube. After immediate vortexing, the solution was centrifuged
(Beckman Coulter Allegra™ X-22R centrifuge with Beckman F0685 fixed angle rotor)
at 10,000 rpm (~10500xg) for 3 minutes to collect precipitated proteins. 1500μL of
supernatants (equivalent to 30μL serum extracts) were carefully transferred into a
2mL centrifuge tube and evaporate to 250μL using speed-vac. The sample is now
ready for deglycosylation.

3.2.4 Deglycosylation
The pH of extracted sample was adjusted to 7.8 using 100mM NH4HCO3
solution. 25 units (5ul 5units/ul solution) of PNGase F were added to each sample and
gently mixed. All samples were incubated at 37℃ overnight. The next day, the
reaction were stopped by freezing samples under -20℃.
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After deglycosylation, 20μL of each sample (equivalent to ~3μL serum
extract) was desalted using C18 Ziptip™ pipette tips following procedures slightly
modified from manufacturer’s instruction. The only change is that we used 10μL of
50% and 80% acetonenitrile each to elute the desalted peptides off Ziptip™ and 2
aliquots were then combined and concentrated to ~2μL before applied on MALDI
target.

3.2.5 MALDI-TOF Pattern Analysis
Desalted samples were applied on stainless steel MALDI target first. After all
samples are applied and dried, 0.3μL of matrix solution (5mg/mL α-CHCA in 50%
acetonenitrile, 0.1% TFA) was applied on top of each sample.
All mass spectra were collected using OminiFLexTM MALDI-TOF mass
spectrometer (Bruker, Bilerica, MA, USA) operated in the linear, positive mode with
delayed extraction turned on. OminiFLexTM MALDI-TOF mass spectrometer uses a
337nm pulsed nitrogen laser, which has a duration of 3ns and a full power of 175µJ.
MS spectra were collected in the range of 700-10000 m/z ratio. All experiments were
performed under 77% of full laser power with sampling rate of 2Hz if not otherwise
specified. 3 sampling points were randomly picked on each sample spot. One hundred
shots per sampling points were accumulated and all 3 sets of spectra were combined
to eliminate on-target fluctuation. For those samples with low signal intensity, the first
10 spectra were discarded to minimize matrix effect and get better signal to noise ratio
within targeted m/z range.
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The mass-spectrometer was calibrated with peptide calibration standard
(1000~4000Da) from Bruker, and all samples were then calibrated externally and
normalized.

3.2.6 LC-MS/MS Analysis and Protein Identification
3.2.6.1 Trypsin Digestion
After MALDI-TOF-MS pattern analysis, samples from GOG bank (18
normal samples and 20 cancer patient samples) were combined into 2 general
mixtures: patient and normal. One half of combined LMW species were concentrated
to 80μL/sample using speed-vac and the PH of the solutions is adjusted to 7.8 using
freshly made 100mM NH4HCO3 if necessary. Trypsin digestion was conducted in
solution using standard procedure with some modifications. In general, there was no
denaturation, reduction, and alkylation before adding trypsin. The first dose of trypsin
was added at a ratio of 1:100 (w/w) and incubated under 37℃ for 4 hours. The second
dose of trypsin (1:50 w/w) was added afterwards and incubated overnight under 37℃.
Tryptical digests were frozen under -20℃ before further analysis.

3.2.6.2 LC-MS/MS Analysis and Protein Identification
The LC-MS/MS analysis was performed on Agilent 1100 HPLC system
coupled in-line with a Bruker HCT 3000plus ESI-IonTrap Mass Spectrometer. 20μL
tryptic digested sample was injected and eluted from a Vydac C18 capillary RP-HPLC
column (10cm, 300µm ID) using the following gradient: 2% B, 10min; 5%-45% B,
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200min; 45%-85% B, 30min; 85%B, 30min. Solvent A is 0.1% formic acid and 1%
acetonitrile in Mili-Q H2O, solvent B is 0.1% formic acid in acetonitrile.
Tandem MS data were searched against NCBInr protein database using an
in-house Mascot server. The search was performed using no enzyme, trypsin,
trypsin+chymotrypsin separately and the results were combined. No taxonomy or
modifications were specified. Peptide mass tolerance is ±1.0Da, MS/MS tolerance is
±0.5Da, and searched for all possible charge states (i.e. +1, +2, +3). The final result
was manually inspected to remove all false positives.

3.3 Results and Discussion
3.3.1 MALDI-TOF Pattern Analysis of GOG Bank Serum Samples
In previous study (see Chapter II), we have demonstrated separating and
enriching low molecular weight proteins/peptides in human serum using an optimized
centrifugal ultrafiltration method. Three marker peaks (1260Da, 1465Da, 1545Da,
respectively) were found and used to distinguish between cancer and normal samples.
In this project, we developed a new organic precipitation method to extract LMW
species from human serum. To validate the efficacy of our method and the markers we
found before, we used MALDI-TOF pattern analysis coupled with this new method to
test the same set of samples from Gynecologic Oncology Group tissue bank (18
normal, 20 patients).
A typical MALDI-TOF pattern comparison of the interested mass range
(1200-1600Da) was shown in Figure 3.1. As could be seen, there are three marker
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peaks which could be used to distinguish cancer patient and normal control. 1260Da
and 1465Da peaks were the same peaks found using centrifugal ultrafiltration method
in previous study. Interestingly, the 1545Da peak disappeared in most of the samples,
and a new 1535Da peak could be detected. If we use peak area ratio
1465Da/1260Da>1 as marker for cancer-positive, 14 out 18 normal samples could be
correctly classified (77.8% specificity), and 1535Da peak was not detectable in most
of

the

normal

samples.

100%

specificity

could

be

achieved

if

using

1466Da/1260Da>2 as marker. In case of sensitivity, 16 of 20 patient samples could be
correctly identified using either 1465Da/1260Da>1 or 1465Da/1260Da>2 as
distinguishing threshold.
There were 3 patient samples (G239, G252, G502) with no signal detected
within 1200-1600Da range using centrifugal ultrafiltration method in previous study.
No signal was detectable in these samples using organic precipitation method either.
Based on the results above, we could conclude that the organic precipitation method
we developed could achieve similar results as in previous study. The specificity is
even better when using optimized cut-off threshold (1465Da/1260Da>2).
According to the SDS-PAGE result from Chertov group [Chertov et al.,
2004], protein precipitation using 50% acetonitrile could not completely separate low
molecular weight species from their carrier proteins; a large amount of LMW species
were still detectable in the precipitated fractions on denaturing gel. This observation
indicated that the rapid denaturation of carrier proteins may result in co-precipitation
of some LMW species bound to them. And only free-phase and less tightly bound
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species could be sufficiently extracted in the supernatant. This could explain why we
got very similar proteomic pattern between organic solvent precipitation method and
non-denaturing centrifugal ultrafiltration method previously developed (data not
shown).
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Figure 3.1 MALDI-TOF MS pattern analysis of serum samples from GOG bank.
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3.3.2 Protein Identification Using LC/MS/MS and Database Searching
Since we could repeatedly detect several marker peaks using two different
methods, the identity of those peaks has to be revealed. LC/MS/MS analysis and
database searching were performed on tryptic digested normal and patient samples.
The

most

important

marker

peak

at

1465Da

was

identified

as

des-alanine-fibrinopeptide A (2-16, DSGEGDFLAEGGGVR, See Figure 3.2). And
the result also indicated that intact fibrinopeptide A (1535Da) and its other fragments
(1350Da, 1263Da, 1206Da) were corresponding to several major peaks detected
within 1200-1600Da mass range in MALDI-TOF patterns. But none of these peaks
had shown consistent correlation with ovarian cancer and therefore wasn’t used as
marker in our study. The intact fibrinopeptide A (1-16, ADSGEGDFLAEGGGVR,
1535Da) is much less abundant than its major fragment - 1465Da - in cancer patient
samples and was not detectable in most of the normal samples (where 1465Da marker
peak is also very weak). According to previous study [Profumo et al., 2005],
des-alanine fibrinopeptide A (fpAY) should be a less abundant form compared with
the original whole peptide after thrombin induced fibrinogen activation. But in our
study, it is the major distinguishing peak and the relative quantity is much higher than
the intact fibrinopeptide A and other fragments in benign and cancer patient samples.
This may indicate some pathological change related to cancer development.
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Figure 3.2 LC/MS/MS analysis and database searching result for marker peak at
1465Da.
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The identity of the 1260Da peak is still unknown even after LC/MS/MS
analysis and database searching. Comparing MALDI-TOF patterns with or without
deglycosylation indicated that the relative intensity of 1260Da peak decreased after
deglycosylation in some samples (see Figure 3.3). This indicated that a N-linked
oligosaccaride was removed after deglycosylation using PNGase F. Enzymatic
deglycosylation treatment made the relative intensity of 1260Da peak more stable and
reliable. It could serve as a good internal standard because it is not related to
fibrinopeptide A and is less affected by the suppression effect generated from high
levels of fibrinopeptide A fragments.
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Figure 3.3 Relative intensity changes of 1260Da marker peak before and after
enzymatic deglycosylation in some samples. It should be noted that the adjacent
1263Da peak is also a fragment of fibrinopeptide A.
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3.3.3 MALDI-TOF Pattern Analysis of Other Sample Sets
Sample collection and preparation have proved to be essential for human
serum proteomic research [Hsieh et al., 2006]. A standardized sampling procedure
was suggested for proteome comparison and biomarker discovery. For samples
collected years ago from different institutions, it is very hard to follow this
recommendation. So, after validation of efficacy of the method and the identification
of the marker peaks using the first GOG bank sample sets, we further tested the
ovarian cancer marker (1465Da/1260Da >2) on other new sample sets.
The first sample set is from Cooperative Human Tissue Network – University
of Pennsylvania Medical Center. This sample set consists of 19 normal serum samples.
One of them was from male donor and therefore being excluded from this study. 15
out of 18 samples (~83%) didn’t show any marker peak within the 1200-1600Da mass
range using MALDI-TOF pattern analysis. Among the 3 samples which have
detectable marker peaks, 2 of them can be classified as normal (1465Da/1260Da <2),
only one sample showed false cancer-positive signal (1465Da/1260Da = 4.64). The
discrepancy observed could be a result of different sample preparing procedure. But
since low overall marker peak intensity is also an important observation in the first
GOG tissue bank normal sample set (no marker peaks were detectable in one of those
samples), we decided to add another distinguishing factor - no marker peaks
detectable (or 1465Da/1260Da =1) - to our marker list for classifying normal samples.
And with this 2 classification factors, we identified 35 out of 36 normal samples
correctly.
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The second sample set is from GOG tissue bank - Columbus Children
Research Hospital. While the first set of GOG tissue bank samples we used were all
collected in year 2003, this second sample set contains samples dated back to 1993
and most of them (41 out of 60) were collected before year 2000. This sample set
contains 40 various carcinoma samples and 20 benign samples in 3 pathological
categories. The MALDI-TOF pattern analysis resulted in a 97.5% (39 out of 40)
sensitivity for carcinoma samples and 85% (17 out of 20 ) for benign samples when
using 1465Da/1260Da >2 as marker. There was no significant difference between
different types of benign and carcinoma samples. But the average level of marker
value was notably elevated from benign to carcinoma. Two sample t-test also proved
significant differences between normal, benign, and cancer sample sets (data not
shown). Detailed statistical analysis was summarized in Table 3.1 and Table 3.2.
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Table 3.1 Statistical analysis of ovarian cancer marker: 1465Da/1260Da
PA

GOG

Normal

Normal

Normal

All

Mean

1.15

0.60

0.87

SD***

0.90

0.30

SE***

0.21

Min

Benign

GOG

GOG

GOG Cancer

Cancer 1

Cancer 2

All

13.74

56.64

49.95

52.18

0.72

13.97

37.79

36.09

36.48

0.07

0.12

3.12

8.45

5.71

4.71

0.11

0.20

0.11

0.94

0.49

3.27

0.49

Max

4.64

1.10

4.64

57.59

100.00**

100.00**

100.00**

Median

1.00*

0.57

1.00*

8.65

49.28

40.74

41.90

N

18

18

36

20

20

40

60

* Marker ratio was manually set to “1” if no marker peaks detectable in normal
samples
** Marker ratio was manually set to “100” if marker ratio is larger than 100 in cancer
patient samples.
*** SD – Standard Deviation, SE – Standard Error

Table 3.2 Elevated marker level correlated to cancer development
Normal

Benign

Carcinoma

1465Da/1260Da>2

1/36 (2.8%)

17/20 (85%)

55/60 (91.7%)

1465Da/1260Da>10

N/A

9/20 (45%)

49/60 (81.7%)

1465Da/1260Da>20

N/A

5/20 (25%)

40/60 (66.7%)
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3.4 Conclusive Remarks
In this project, we have demonstrated a novel organic precipitation method
coupled with enzymatic deglycosylation to extract cancer related markers from low
molecular weight portion of human serum proteome. Several marker peaks were
robustly detected and validated in different clinical sample sets. The identification of
these markers was determined by tandem mass spectrometry coupled with database
searching. Interestingly, most of the major peaks detected were derived from
fibrinopeptide A – a product of thrombin induced fibrinogen activation.
Fibrinogen is the main protein of blood coagulation system. It is a large
protein (MW 340 kDa) in human and it consists of two identical subunits that contain
three polypeptide chains: α, β and γ. Fibrinopeptide A (1 – 16 amino acids) and B (1 –
17 amino acids) are released by thrombin from the N terminal parts of α- and β-chains,
respectively. In this way fibrinogen is converted into fibrin, which forms a fibrin clot
by polymerization [Maurer et al., 2000]. Pathological hemostasis activation often
occurs in cancer patients [Wojtukiewicz et al., 2000]. And the presence of fibrin in
and around tumors may be essential for tumor growth [Zacharski et al., 1990]. While
there is no direct correlation between plasma FPA levels and plasma fibrinogen
concentration, extravascular metabolism of fibrinogen and formation of fibrin in or
around tumor may account for the leakage of FPA into the circulation [Wilner et al.,
1978] and therefore responsible for abnormally elevated circulating FPA levels.
A correlation between elevated plasma level of FPA and ovarian cancer was
reported previously [Gadducci et al., 1994]. Using competitive enzyme-linked
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immunoassay (cELISA) to measure FPA levels, they have achieved very high
specificity (100%) and fair sensitivity (64%) in distinguishing ovarian carcinoma
patients from benign or controls. But they also concluded that there was no difference
in FPA level between benign and controls. The antibody used in cELISA is able to
capture all FPA related fragments as long as they still contain the recognition site.
This will limit the differentiation power when there are metabolic fragments hanging
around. In our study, the application of MALDI-TOF MS pattern analysis provided an
accurate tool of measuring interested molecules. The real cancer related molecule
could be well distinguished from others. Much higher sensitivity and the capability of
distinguishing benign ovarian diseases from controls and cancer patients were two
major benefits. The mechanism of high level des-alanine fibrinopeptide A and its
correlation with ovarian cancer is still unknown. Orvisky and colleagues reported a
down-regulated serum des-alanine FPA level in hepatocellular carcinoma [Orvisky et
al., 2006]. This observation indicated that the level of circulating des-alanine
fibrinopeptide A is cancer pathology specific and more research should be done to
elucidate the mechanism.
As an additional procedure before MALDI-TOF pattern analysis, enzymatic
deglycosylation proved to be critical for signal clean up and quantification.
Peptide-N-glycosidase F (PNGase F) is one of the most widely used enzymes for the
deglycosylation of glycoproteins. The enzyme releases asparagine-linked (N-linked)
oligosaccharides from glycoproteins and glycopeptides, and the substrate could be as
small as a tripeptide (Asn-Xaa-Ser/Thr, where X can be any amino acid, except Pro).
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The removal of glycans was especially beneficial in normal samples which generate
much less abundant signals and are readily to be affected by suppression effects (data
not shown). The identity of 1260Da marker peak should be further studied, and it’s
highly probable to be a glycopeptide (see Figure 3.3).
As a conclusion, we have developed a novel organic solvent precipitation
method for separating and enriching low molecular weight species from human serum.
An enzymatic deglycosylation step was used before MALDI-TOF MS pattern
analysis to improve data quality and marker quantification. Elevated circulating
Des-alanine fibrinopeptide A level was found to have correlation with development of
ovarian cancer. The whole procedure is simple and the results are exiting.
Preoperative plasma may be a better sample system for validating markers found in
this study. More clinical samples sets should be tested with standardized collecting
and preserving protocols.

67

References

B-L Adam, Y. Qu, J.W. Davis, et al., “Serum protein fingerprinting coupled with a
pattern-matching algorithm distinguishes prostate cancer from benign prostate
hyperplasia and healthy men”, Cancer Res., 62:3609-3614 (2002)

J.N. Adkins, S.M. Varnum, K.J. Auberry, et al., “Toward a Human Blood Serum
Proteome”, Molecular & Cellular Proteomics, 1:947-955 (2002)

G. Alexe; S. Alexe; L.A. Liotta, et al., “Ovarian cancer detection by logical analysis of
proteomic data”, Proteomics, 4:766-783 (2004)

American Cancer Society, “Cancer facts and figures”, Altanta: American Cancer
Society, (1996)

J. An, J-Y Sun, Q. Yuan, et al., “Proteomics analysis of differentially expressed
metastasis-associated proteins in adenoid cystic carcinoma cell lines of human
salivary gland”, Oral Oncology, 40:400-408 (2004)

N.L. Anderson and N.G. Anderson, “The Human Plasma Proteome: History, Character,
and Diagnostic Prospects”, Molecular & Cellular Proteomics, 1:845-867 (2002)

68

J.M. Arthur, V. Thongboonkerd, J.A. Scherzer, et al., “Differential expression of
proteins in renal cortex and medulla: A proteomic approach”, Kidney International,
62:1314-1321 (2002)

L.L. Banez, P. Prasanna, L. Sun, et al., “Diagnostic potential of serum proteomic
patterns in prostate cancer”, J. Urol., 170:442-446 (2003)

R.E. Banks, M.J. Dunn, D.F. Hochstrasser, et al., “Proteomics: new perspectives, new
biomedical opportunities”, Lancet 356:1749-1756 (2000)

S. Beranova-Giorgianni, “Proteome analysis by two dimensional gel electrophoresis
and mass spectrometry: strengths and limitations”, Trends in Analytical Chemistry, 22,
No. 5 (2003)

P. Chaurand, B.B. DaGue, R.S. Pearsall, et al., “Profiling proteins from
azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser
desorption/ionization mass spectrometry”, Proteomics, 1:1320-1326 (2001)

S. Curry, “Beyond expansion: structural studies on the transport roles of human serum
albumin”, Vox Sang, 83, Suppl. 1:315-319 (2002)

E.P. Diamandis, “Mass Spectrometry as a Diagnostic and a Cancer Biomarker

69

Discovery Tool: Opportunities and Potential Limitations”, Molecular & Cellular
Proteomics, 3:367-378 (2004)

D.B. Friedman, S. Hill, J.W. Keller, et al., “Proteome analysis of human colon cancer
by two-dimensional difference gel electrophoresis and mass spectrometry”,
Proteomics, 4:793-811 (2004)

A. Görg, C, Obermaier, G, Boguth, et al., “The current state of two-dimensional
electrophoresis with immobilized pH gradients” Electrophoresis, 21, No. 6:1037-1053
(2000)

D.J. Grossklaus, J.A. Smith, S.B. Shappell, et al., “The free/total prostate-specific
antigen ratio is the best predictor of tumor involvement in the radical prostatectomy
specimen among men with an elevated PSA”, Urol. Oncol., 7(5):195-198 (2002)

A.E. Guppy and G.J. Rustin, “CA125 response: can it replace the traditional response
criteria in ovarian cancer?”, Onologist, 7(5):437-443 (2002)

S.P. Gygi, B. Rist, S.A. Gerber, et al., “Quantitative analysis of complex protein
mixtures using isotope-coded affinity tags”, Nat. Biotechnol., 17:994-999 (1999)

R.L. Hamler, K. Zhu, N.S. Buchanan, et al., “A two-dimensional liquid-phase

70

separation method coupled with mass spectrometry for proteomic studies of breast
cancer and biomarker identification”, Proteomics, 4:562-577 (2004)

P.A. Haynes, S.P. Gygi, D. Figeys, et al., “Proteome analysis: biological assay or data
archive?”, Electrophoresis 19:1862–1871 (1998)

D.F. Hochstrasser, “Proteome in perspective”, Clin Chem Lab Med, 36:825–836
(1998)

T.W. Hutchens and T.T. Yip, “New desorption strategies for the mass spectrometric
analysis of macromolecules”, Rapid Commun. Mass Spectrom., 7:576-580 (1993)

T.C. Hunter, N.L. Andon, A. Koller, et al., “The functional proteomics toolbox:
methods and applications”, Journal of Chromatography B, 782:165-181 (2002)

D. Jiang, W. Ying, Y. Lu, et al., “Identification of metastasis-associated proteins by
proteomic analysis and functional exploration of interleukin-18 in metastasis”.
Proteomics, 3:724-737 (2003)

J. Klose and U. Kobalz, “Two-dimensional electrophoresis of proteins: an updated
protocol and implications for a functional analysis of the genome”, Electrophoresis,
16(6):1034-1059 (1995)

71

K.R. Kozak, M.W. Amneus, S.M. Pusey, et al., “Identification of biomarkers for
ovarian cancer using strong anion-exchange Proteinchips: Potential use in diagnosis
and prognosis”, PNAS, 100:12343-12348 (2003)

K. Kubota, K. Wakabayashi and T. Matsuoka, “Proteome analysis of secreted proteins
during osteoclast differentiation using two different methods: 2D-GE and ICAT
analysis with 2D HPLC”, Proteomics, 3:616-626 (2003).

S. Lehrer, J. Roboz, H. Ding, et al., “Putative protein markers in the sera of men with
prostatic neoplasms”, B.J.U.Intl., 92:223-225 (2003)

Andrew J. Link, Jimmy Eng, David M. Schieltz et al., “Direct analysis of protein
complexes using mass spectrometry”, Nature Biotechnol., 17:676-682 (1999)

R.R.O. Loo, T.I. Stevenson, C. Mitchell, et al., “Mass spectrometry of proteins
directly from polyacrylamide gels”, Anal Chem, 8:1910–1917 (1996)

K.L. Meehan and M.D. Sadar, “Quantitative profiling of LNCaP prostate cancer cells
using isotope-coded affinity tags and mass spectrometry”, Proteomics, 4:1116-1134
(2004)

M.P. Molloy, S. Donohoe, E.E. Brzezinski, et al., “Large-scale evaluation of

72

quantitative reproducibility and proteome coverage using acid cleavable isotope
coded affinity tag mass spectrometry for proteomic profiling”, Proteomics,
5:1204–1208 (2005)

R.S. Negm, M. Verma and S. Srivastava, “The promise of biomarkers in cancer
screening and detection”, Trends in Molecular Medicine, 6(6):288-293 (2002)

W.F.

Patton,

“Detection

technologies

in

proteome

analysis”,

Journal

of

Chromatography B, 771:3-31 (2002)

E.F. Petricoin III, A. Ardekani , B. Hitt, et al., “Use of proteomic patterns in serum to
identify ovarian cancer”, Lancet, 359:572-577 (2002)

E.F. Petricoin III, D.K. Ornstein, C.P. Paweletz, et al., “Serum proteomic patterns for
detection of prostate cancer”, J. Natl. Cancer Inst., 94:1576-1578 (2002)

E.F. Petricoin and L.A. Liotta, “SELDI-TOF-based serum proteomic pattern
diagnostics for early detection of cancer”, Current Opinion in Biotechnology,
15:24-30 (2004)

E. Petricoin, J. Wulfkuhle, V. Espina, et al., “Clinical Proteomics: Revolutionizing
Disease Detection and Patient Tailoring Threapy”, Journal of Proteome Research,

73

3:209-217 (2004)

Y. Qu, B-L Adam, Y. Yasui, et al., “Boosted decision tree analysis of surface-enhanced
laser desorption/ionization mass spectral serum profiles discriminated prostate cancer
from nonprostate patients”, Clin. Chem., 48:1835-1843 (2002)

T. Reynolds, “For proteomics research, a new race has begun”, J Natl Cancer Inst,
94:552-554 (2002)

A.K. Sato, D.J. Sexton, L.A. Morganelli, et al., “Development of mammalian serum
albumin affinity purification media by peptide phage display”, Biotechno. Prog.,
18:182-192 (2002)

B. Schulenberg, J.M. Beechem and W.F. Patton, “Mapping glycosylation changes
related to cancer using the Multiplexed Proteomics technology: a protein differential
display approach”, Journal of Chromatography B, 793:127-139 (2003)

Y. Shen, R. Zhao, S.J. Berger, et al., “High-efficiency nanoscale liquid
chromatography coupled on-line with mass spectrometry using nanoelectrospray
ionization for proteomics”, Anal. Chem., 74:4235-4249 (2002)

Y. Shen, J.M. Jacobs, D.G. Camp, et al., “Ultra-high-efficiency strong cation exchange

74

LC/RPLC/MS/MS for high dynamic range characterization of the human plasma
proteome”, Anal. Chem., 76:1134-1144 (2004)

A. Shevchenko, M. Wilm, O. Vorm, et al., “Mass Spectrometric Sequencing of
Proteins from Silver-Stained Polyacrylamide Gels” Analytical Chemistry, 68:850- 858
(1996)

M.B. Smolka, H. Zhou, S. Purkayastha, et al., “Optimization of the isotope-coded
affinity tag-labeling procedure for quantitative proteome analysis”, Analytical
Chemistry, 297:25-31 (2001)

P.R. Srinivas, M. Verma, Y. Zhao, et al., “Proteomics for Cancer Biomarker
Discovery”, Clin. Chem., 48(8):1160-1169 (2002)

T. Stasyk and L.A. Huber. “Zooming in: Fractionation strategies in proteomics”,
Proteomics, 4:3704–3716 (2004)

N. Tang, P. Tornatore and S.R. Weinberger, “Current developments in SELDI affinity
technology”, Mass Spectrometry Reviews, 23:34-44 (2004)

W.A. Tao and R. Aebersold, “Advances in quantitative proteomics via stable isotope
tagging and mass spectrometry”, Current Opinion in Biotechnology, 14:110-118

75

(2003)

R.S. Tirumalai, K.C. Chan, D-R.A. Prieto, et al., “Characterization of the low
molecular weight human serum proteome”, Molecular & Cellular Proteomics,
2(10):1096-1103 (2003)

M. Verma, G.L. Wright, Jr, S.M. Hanash, et al., “Proteomic approaches within the NCI
early detection research network for the discovery and identification of cancer
biomarkers”, Ann N Y Acad Sci, 945:103-115 (2001)

R. Vitorino, M.J.C. Lobo, A.J. Ferrer-Correira, et al., “Identification of human whole
saliva protein components using proteomics”, Proteomics, 4:1109-1115 (2004)

Y. Wagner, A. Sickmann, H.E. Meyer, et al., “Multidimensional Nano-HPLC for
Analysis of Protein Complexes”, J. Am. Soc. Mass Spectrom., 14:1003-1011 (2003)

M.P. Washburn, D. Wolters and J.R. Yates, III, “Large Scale analysis of the yeast
proteome via multidimensional protein identification technology”, Nat. Biotechnol.,
19:242-247 (2001)

V.C. Wasinger, S.J. Cordwell, A. Cerpa-Potjak, et al., “Progress with gene-product
mapping of the Mollicutes: mycoplasma genitalium” Electrophoresis, 16:1090–1094

76

(1995)

M.R. Wilkins, J.C. Sanchez, A.A. Gooley, et al., “Progress with proteome projects:
why all proteins expressed by a genome should be identified and how to do it”,
Biotechnol Genet Eng Rev, 13:19–50 (1996)

D.A. Wolters, M.P. Washburn and J.R. Yates, III, “An automated Multidimensional
Protein Identification Technology for Shotgun Proteomics”, Anal. Chem.,
73:5683-5690 (2001)

J.D. Wulfkuhle, L.A. Liotta and E.F. Petricoin, “Proteomic Applications for the Early
Detection of Cancer”, Nature Rev., Cancer, 3: 267-275 (2003)

H. Zhang, W. Yan and R. Aebersold, “Chemical probes and tandem mass spectrometry:
a strategy for the quantitative analysis of proteomes and subproteomes”, Current
Opinion in Chemical Biology, 8:66-75 (2004)

H. Zhou, J.A. Ranish, J.D. Watts, et al., “Quantitative proteome analysis by
solid-phase isotope tagging and mass spectrometry”, Nat. Biotechnol., 20: 512-515
(2002)

77

PART II
TECHNOLOGY DEVELOPMENT FOR GENOMIC BIOMARKER
ANALYSIS

78

CHAPTER IV
GENERAL INTRODUCTION

4.1 Single Nucleotide Polymorphisms (SNPs) Detection
4.1.1 What are Single Nucleotide Polymorphisms (SNPs)?
Single Nucleotide Polymorphisms (SNPs) are single base substitutions that
occur at a specific position in a genome (Figure 4.1.1a). Single-base insertions and
deletions are not strictly SNPs, but they are often included under this genetic
definition (Figure 4.1.1b). In general, the rare (less frequent) allele has an abundance
of 1% or greater in a population, otherwise it is referred to as point mutation [Brookes,
1999]. In diploid species as humans, SNPs are usually biallelic (a SNP has two alleles
and three or four alleles are very rare). Averagely speaking, one SNP could be found
every 300 to 1000 bases in humans. They are estimated to represent as much as 90%
of all genetic variations [Cooper et al., 1985].

79

Figure 4.1.1 (a) The two alleles of a single nucleotide polymorphism; (b) a single
nucleotide deletion/insertion.
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1.42 million SNPs were reported [Sachidanandam et al., 2001] and now there are
more than 6 million mapped human SNPs in public databases [Collins et al., 2003].
Only a small portion of located SNPs lie within coding regions (cSNPs) and an even
smaller percentage will result in sequence changes in expressed proteins. However,
non-coding SNPs can still influence mRNA stability and conformation, as well as the
quantity and quality of gene expression product. To geneticists, it is highly valuable if
a marker can be pinpointed directly in the genomic region of interest. An allele of a
SNP can be an important genetic risk factor as it may increase susceptibility to certain
diseases. Due to their biallelic nature, SNPs are fairly easy to detect in genotyping and
data interpretation can be automated.

4.1.2 Genotyping SNPs Using MALDI-TOF Mass Spectrometry
Numerous approaches have been developed in genotyping SNPs. Criteria
such as accuracy of SNP detection, sensitivity to identify SNPs using a small amount
of template, throughput, and flexibility of the procedure were thoroughly explored.
Traditional methods based on molecular biology techniques often lack essential
features for clinical settings such as accuracy, automation, and throughput. In terms of
robustness, accuracy, reproducibility, and success rates, mass spectrometry assays
based on primer extension reactions surpassed most other methods in side by side
comparison [Le Hellard et al., 2002].
All methods for SNP genotyping combine two fundamental steps: the
generation of an allele-specific product, and the analysis thereafter. Currently, four
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major methodologies are used for the generation of the allele-specific products:
hybridization, ligation, cleavage, and primer extension. All of these methods for allele
discrimination have been combined with MALDI-TOF analysis [Tost and Gut, 2005].
The most widely applied method for allele distinction in SNP genotyping and point
mutation analysis is primer extension [Syvänen et al., 1990]. Several types of primer
extension assays using MALDI-TOF MS as the detection platform have been
developed. Differentiation of the alleles is basically achieved by three different
strategies: single base primer extension (SBE), multiple base primer extension, and
nucleotides depletion. Each extension product of a SNP is detected based on their
mass differences. In single base primer extension, this is due to the addition of
nucleotides that naturally differ in mass, and in multiple base primer extension, the
addition of a different number of bases will distinct alleles.
For single base primer extension (SBE) reaction, the primer anneals
immediately next to the polymorphic site and terminating dideoxynucleotides
(ddNTPs) were used in extension reaction. Therefore, unlike in regular PCR reaction,
the primer is only extended with a single nucleotide. This approach is applied in the
PinPoint assay [Haff and Smirnov, 1997], and commercialized by Applied Biosystems
as the SequazymeTM PinPoint SNP Typing Kit. The reaction procedure is outlined in
Figure 4.1.2.

82

Figure 4.1.2 The reaction procedure of the PinPoint assay [Haff and Smirnov, 1997].
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The GOOD assay was introduced by Sauer and colleagues [Sauer et al.,
2000a,b]. Utilizing a chemical modification strategy – charge tagging [Gut et al.,
1997], this assay doesn’t require purification step prior to MALDI analysis. It reduces
the extension products to a core-sequence of four to five nucleotides that contain the
allele information by enzymatic digestion and could increase signal intensity to up to
100 fold.
Other methods like the solid phase capturable single base extension
(SPC-SBE) assay [Kim et al., 2002] and the genoSNIP assay [Wenzel et al., 2003] are
also based on single base primer extension principle. The SPC-SBE assay
distinguishes itself from other assays by using biotinylated ddNTPs and only extended
products are retained on target. Non-extended primers were eliminated and therefore
increased the possibility of multiplexing. The genoSNIP assay is characterized by
using photocleavable primers.
Since the smallest mass difference between two nucleotides (A and T) is only
9 Da, analysis of some SNPs may be difficult by SBE assays. To enhance the allele
distinction in the mass spectrum, a mixture of deoxynucleotides (dNTPs) and
dideoxynucleotides (ddNTPs) were used in multiple base primer extension principle.
The primer anneals again immediately adjacent to a SNP site, one allele is extended
by only one base (ddNTPs) while the second one by two or more (termination occurs
at the first nucleotide in the template complementary to a ddNTP). This strategy could
generate extension products with a mass difference of at least 300 Da. With enhanced
allele discrimination, this concept is used in the primer oligo base extension (PROBE)
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assay [Braun et al., 1997], the MassEXTEND assay [Leushner and Chiu, 2000]
(Sequenom), and the very short extension (VSET) assay [Sun et al., 2000]. A
schematic representation of PROBE assay is shown in Figure 4.1.3.
The MassEXTEND assay is an improved version of the original PROBE
assay. It uses ion-exchange resin for sample conditioning, avoided biotinylated
primers and immobilization as used in the PROBE assay. Extremely small volumes
(nanoliter) of samples are transferred onto silicon target pre-spotted with
3-hydroxypicolinic acid (HPA) matrix. As the entire sample spot is volatilized with a
few laser pulses, the need for searching sweet spots of the HPA matrix is avoided.
The very short extension (VSET) assay was designed to address some of the
problems associated with both the original PinPoint and the PROBE assay. In contrast
to the original PROBE assay, three ddNTP and one dNTP were used in primer
extension reaction. As a result, for one allele, extension is one base and for the other
are two bases, which separates the alleles by a mass of about 300 Da.
Nucleotide depletion genotyping assay (NUDGE) is essentially a variant of
multiple base primer extension strategy. This method was reported by Decode
Genetics recently [Blondal et al., 2003] and the primer is designed to anneal two bases
upstream of the polymorphic site. The allele is discriminated in the presence of only
three deoxynucleotides. The one that is complementary to one allele of the SNP is
depleted. Therefore, termination occurs right next to the polymorphic position for one
allele, while for the other allele, extension will not stop until the first nucleobase in
the template complementary to the depleted dNTP.
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Figure 4.1.3 The PROBE assay [Braun, Little and Köster, 1997]. The biotin-label is
shown as a black circle, which is captured in streptavidin-coated microtiter plates.
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However, analysis of nucleic acids by MALDI mass spectrometry has some
drawbacks. MALDI-TOF mass spectrometry is very sensitive to the presence of metal
ions. Due to the multiple negatively charged sugar phosphate backbone of DNA
molecule, it is susceptible to form adduct with common cations such as Na+ and K+.
Peak broadening and reduction of resolution, sensitivity and accuracy are direct
consequences of adduct formation. As cations such as sodium and potassium are
highly abundant in buffers for molecular biology reactions, stringent purification
procedures need to be applied. Approaches to overcome adduct formation are mostly
based on ion-exchange principles. This could be done either on solid-phase [Tang et
al., 1995] or through cation-exchange resin methods [Nordhoff et al., 1992]. The
addition of ammonium containing organic modifiers to the matrix reduces
heterogeneity of oligonucleotide ions caused by cation adducts. The ammonium is
volatile and could be dissociated from the analyte molecules during laser pulse
bombardment, and therefore leaving the analyte in free acid form. Diammonium
citrate and tartrate are reported to be good choices serving this purpose [Pieles et al.,
1993; Lecchi and Pannell, 1995].
The other drawback for MALDI-TOF mass spectrometry lies in the sample
deposition method. The standard method for sample preparation is called
dried-droplet method. In this method, a small drop (usually about 0.5µL) of sample
solution is applied on a drop of prepared matrix solution (usually about 1µL) and
allowing the mixture to dry. During the crystallization of matrix, analyte molecules
were also redistributed and “sweet spots” were formed. The existence of
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heterogeneous “sweet spots” will reduce the sensitivity and accuracy when applying
MALDI-TOF in SNP analysis. Nanoliter liquid deposition technology was used to
overcome “sweet spots” formation, but this will greatly limit the quantity of analyte
loaded.
Choices of matrices, combination of sample conditioning prior to mass
spectrometry analysis and sample preparation are all essential components of
successful analysis of SNPs using MALDI-TOF mass spectrometry. Novel strategy is
always needed and being continuously developed to improve the sensitivity, accuracy,
and cost effectiveness of mass spectrometry based genotyping.

4.2 Microsatellite Instability Detection
4.2.1 Microsatellite Instability and Cancer
Microsatellites are one of the most abundant classes of intergenic repetitive
sequences dispersed in the eukaryotic genome and contain repetitive units composed
of one to five base pairs [Weber et al., 1989; Litt et al., 1989; Dib et al., 1996]. These
sequences, as well as minisatellite sequences, are highly polymorphic in human
populations and could be used as a marker for human identification or pedigree
analyses [Hearne et al., 1992]. During the progress of the Human Genome Project,
numerous microsatellite loci have been pinpointed on the human genome and are now
being used for various genomic analyses.
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Figure 4.2.1 (A) Normal replication event of MS DNA; (B) strand slippage event
initiating an abnormal replication; (C)effective repair leading to normal replication
(A=C); (D) defective repair of B leading to microsatellite instability (A≠D). [Samara
et al., 2006]
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Compared with other regions on the genome, these repetitive sequences were
thought to be stable within the life span of organisms. However, microsatellites are
mainly located in non-coding regions (introns) of genome. Due to their repetitive
characteristics, they are likely to be the site of insertion and deletion mutations during
DNA replication, with an error rate of 1 in 100,000 base pairs copied. The majority of
these errors could be detected and corrected by the inherent proof reading capabilities
of DNA polymerases. A small proportion of mismatches that are missed by this
mechanism are normally identified and corrected by a group of proteins named the
mismatch repair (MMR) system [Fishel, 1999]. Dysfunction of the MMR system
allows the accumulation of replication errors and leads to microsatellite instability
[Strand et al., 1993], which could be defined as “a change of any length due to either
insertion or deletion mutations of repeating units in a microsatellite" [Boland et al.,
1998]. A representative scheme of MSI is shown in Figure 4.2.1.
Microsatellite alterations can be found in a number of tumors. There are two
types of alterations: loss of heterozygosity (LOH), which can be detected in the
majority of colorectal cancers (CRC), and microsatellite instability (MSI). Instability
of a class of microsatellites with dinucleotide repeats was initially reported in
colorectal cancer [Thibodeau et al. 1993; Ionov et al., 1993; Aaltonen et al., 1993] and
in patients with hereditary non-polyposis colorectal cancer (HNPCC) [Peltomaki et al.,
1993]. Because mutations in genes functioning in DNA mismatch repair were found
to be inherited in pedigrees of HNPCC, microsatellite instability was regarded as an
important phenotype of deficiency in DNA mismatch repair and as a marker of a high
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risk for cancer. High-degree microsatellite instability (MSI-H) is a feature of most
colorectal cancers arising as part of the hereditary non-polyposis colorectal cancer
(HNPCC) as well as 15–20% of sporadic colorectal cancers [Haydon et al., 2002].
And it was reported that all colorectal cancers display some degree of microsatellite
instability if enough markers are studied [Umar et al., 2004].
As a potential marker, MSI were also investigated in other cancers. The
results are rather contradictory, though. For example, Mao and colleagues [Mao et al.,
1994; 1996] observed high frequency microsatellite instability in transitional cell
carcinoma (TCC) of bladder with both tumor DNA and DNA extracted from urine.
But other researches demonstrated much lower frequency, or lack of correlation in
TCC pathological data with MSI [Catto et al., 2004].
Siah and colleagues reported low detection rate of MSI in early-onset breast
cancer patients [Siah et al.; 2000]. Two of the most recommended MSI marker,
BAT-25 and BAT-26, failed to show any MSI in tumor DNA. While Wild and Murata
all reported successful detection of MSI with a relatively higher detection rate [Wild
et al., 2000; Murata et al., 2002].
The discrepancy of results could be greatly related to the experimental design.
Choices of markers, sources and handling of clinical samples, researchers’ standard of
MSI categorization and MSI detection methods can all be distinguishing factors
among studies. More work should be done to develop accurate and objective assay
systems so that the clinicopathologic features of microsatellite instability could be
revealed.
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4.2.2 Microsatellite Instability Detection
4.2.2.1 Markers for Detecting Microsatellite Instability
In 1997, an International Collaborative Group announced guidelines for the
identification and assessment of microsatellite instability [Boland et al., 1998]. They
classified tumors into microsatellite stable (MSS) and two groups of microsatellite
unstable cancers based on their degree of instability: high (MSI-H) or low (MSI-L).
BAT-25 and BAT-26, two mononucleotide microsatellite markers, and three
dinucleotide markers (D2S123, D5S346 and D17S250) were chosen as a panel to be
studied for determining MSI status. Tumors displaying instability in two or more
markers were designated MSI-H, instability in only one marker was designated
MSI-L and if no markers were affected the tumor was designated MSS. There is now
a growing consensus that the pathological phenotype of MSI-H is characterized
particularly by instability in the mononucleotide markers [Umar et al., 2004].
Colorectal cancers with MSI-H demonstrated unique biological behavior while MSI-L
cancers are less well characterized and are often grouped with cancers that are
categorized as MSS [Gonzalez-Garcia et al., 2000].
More and more markers were tested in different research approaches. It was
generally proved that the detection efficiency could be improved using expanded
marker panels. And besides the mono- and dinucleotide markers originally defined on
the NCI workshop, markers with longer sequence instability (tetranucleotide repeats,
for example) demonstrated some advantages in cancer detection [Catto et al., 2003].
The hMLH1 promoter region was reported to be highly methylated in about 80% of
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microsatellite instability MSI (+) colorectal cancers, but in none of the MSI (-)
colorectal cancers [Masato Maekawa et al., 1999]. The correlation between hMLH1
gene hypermethylation and MSI was also reported in T cell lymphoma [Scarisbrick et
al., 2003]. These findings could be a good lead to the pathological features behind
MSI.

4.2.2.2 Methods for Microsatellite Instability Detection
Usually, a set of microsatellite markers is amplified by PCR followed by gel
or capillary electrophoresis to separate PCR amplicons. Various detection method
have been applied to illustrate the markers amplified, such as autoradiography
[Thibodeau et al, 1993], silver staining [Schlegel et al, 1996], or fluorescence
techniques [Gyapay et al, 1996]. The representative results using different methods
are shown in Figure 4.2.2 and Figure 4.2.3.
Autoradiography method is using radiolabeled (32P) oligonucleotide primers
during polymerase chain reaction (PCR). The amplified products are electrophoresed
on a sequencing gel and visualized using X-ray developed films. Silver stain is an
alternative band visualization method for polyacrylamide gel electrophoresis (PAGE)
without involving radioactive isotopes. Both methods suffer the known disadvantages
of PAGE, such as migration error, low sensitivity and cumbersome procedures.
Newly developed fluorescence based sequencing method could overcome all
problems mentioned above [Oda, et al., 1997].
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Figure 4.2.2 A representative example (case #28) of microsatellite instability in
gastric cancers (radioactive electrophoresis method). T: tumor samples; and N:
corresponding normal samples. Microsatellite markers are shown on the top of the
gels. Bands of abnormal size are detected in all tumor lanes of case #28 [Yamada et
al., 2002].
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Figure 4.2.3 Variation of MSI profile among different regions in MSI tumors.
Amplification of D2S123 microsatellite in 3 different regions of case 109. This is a
homozygote marker with 1 normal allele of 121 bp. Three unstable alleles are
amplified in region A, only 1 in region B, and 2 in region C [Danjoux et al., 2006].
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The separation power of capillary electrophoresis combined with high
throughput automated instrumental design could make fluorescence based sequencing
a standard routine for MSI analysis.
Other than the widely adapted strategies, researchers have applied newly
developed technologies in MSI analysis and cancer detection. Dietmaier and
colleagues have established a technique to detect MSI by LightCycler Real-time PCR
and melting point analysis [Dietmaier et al., 2001]. Amplification of microsatellites
by real-time PCR is followed by melting point analysis to display alterations in the
length of repetitive sequences. According to their results, amplification and melting
point determination of BAT26 and BAT25 was achieved in 129/162 (80%) and
123/162 (76%) formalin-fixed and paraffin-embedded tissue samples, respectively.
Moreover, MSI could be detected only in MSI-high tumors using both BAT25 and
BAT26 markers. This new technique allows MSI detection within 1 hour and
provides an alternative way for fast, high-throughput MSI analysis.
Denaturing

high-performance

liquid

chromatography

(DHPLC)

was

compared side by side with fluorescence capillary electrophoresis (FCE) in MSI
detection [Deschoolmeester et al., 2006]. Developed by a Korean group in 2003 [Kim
et al., 2003], this method was proved to be as effective as FCE on quasimonomorphic
BAT markers, but hard to interpret for the detection of dinucleotide markers.
Clinicopathologic features of microsatellite instability positive cases have
remained unclear. Introducing automated sequencer for microsatellite assay was a
breakthrough for MSI analysis and cancer detection. The use of dual
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fluorescence-labeled primers and an automated sequencer is recommended for
accurate detection. However, to improve MSI detection using highly complicated
clinical samples other than malignant tissues, novel sample preparation and PCR
strategy has to be developed.
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CHAPTER V
MATRIX-ASSISTED LASER DESORPTION/IONIZATION
TIME-OF-FLIGHT ANALYSIS OF LOW-CONCENTRATION OF
OLIGONUCLEOTIDES AND MINI-SEQUENCING PRODUCTS

5.1 Introduction
The genotyping method based on matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF MS) is one of the most promising
approaches to large scale genotyping of single nucleotide polymorphisms (SNPs)
[Braun et al., 1997a,b; Haff et al., 1997a,b; Hihhins et al., 1997; Little et al., 1997a,b,c;
Fei et al., 1998; Fu et al., 1998; Ross et al., 1998; Chen et al., 1999; Griffin et al.,
1999; Li et al., 1999; Sun et al., 2000], as MALDI-TOF is fast, provides higher
accuracy in molecular weight data, and requires no fluorescent or radioactive labeling.
However, these advantages are somewhat not match well to mini-sequencing, the
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most widely used sequencing reaction employed in genotyping. This is evident by the
fact that the overall detection limit of a MALDI-TOF based genotyping method is
significantly poorer than that of fluorescent-based detection, though MALDI-TOF
itself is extremely sensitive. The poor detection limit leads to a significant increase in
genotyping costs and difficulty in designing multiplexed assays.
This mismatch is due to the fact that, unlike other methods, MALDI utilizes a
very small portion of sequencing products for data acquisition. In MALDI, each laser
shot targets a spot of ~100μm2. In general the MALDI sensitivity is, to a large extent,
dictated by the amounts of the analyte present on the targeted spot, rather than total
quantities loaded. In other words, the more analytes that are present on the targeted
spot, the higher the sensitivity will be. Conventional methods use a metal sample
substrate. The aqueous solution of 3-HPA/DNA tends to spread to a large area on the
metal surface as a result of strong interactions between metal and polar solvents. For
example 0.5μL of aqueous solution can spread to an area of 1.5 mm in diameter. The
formation of a large-area sample inevitably reduces the oligonucleotide quantity in a
targeted spot, thus reducing sensitivity. Clearly, an ideal sample preparation method
should deposit most, if not all, of the mini-sequencing products onto a target, and
more importantly it should produce the smallest possible sample area so that the
deposited molecules can be maximally assessed by the same laser shot. Other
essential requirements for a good sample preparation method include good sample
homogeneity for fast automatic data acquisition, and good sample-to-sample and
spot-to-spot reproducibility for quantitative analysis.
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Recently, we reported a shrinkage strategy in which a hydrophobic surface
was used as the sample substrate [Hung et al., 1998]. The hydrophobic nature of the
sample substrate forces the aqueous drop to shrink to a small area thereby
concentrating analyte molecules on target. More recently, Nordhoff and coworkers
extended this method by adding a small hydrophilic spot, which acts as an anchor that,
if touched, holds the sample droplet and directs crystallization onto it [Schuerenberg
et al., 2000]. Two sample loading procedures have been investigated. The first one
shrinks the matrix solution first, followed by adding the DNA solution onto the top of
the dried matrix film [Hung et al., 1998; Huang et al., 1999]. The second procedure
shrinked the aqueous solution containing both matrix and analyte [Schuerenberg et al.,
2000]. These methods work well when applied t analysis of high-concentration
oligonucleotides, but did not work well with low-concentration oligonucleotides, at
least in our hand, in terms of sensitivity and reproducibility. In addition, both
procedures involve the shrinkage of the solution containing the matrix on a
hydrophobic surface, but it is difficult to control the shrinkage of the aqueous 3-HPA
solution. It was observed that if too much matrix was loaded, much larger sample
areas were formed. If too little matrix was loaded, the sample quality is poorer.
In this work, we developed a new procedure in which a few μL of the
oligonucleotide solution are first deposited on the target, followed by addition of a
small volume (0.1μL) of saturated 3-HPA solution. It is seen that this procedure is
superior to existing procedures, and can substantially improve the MALDI sensitivity
and sample homogeneity. The application of this procedure on low-concentration
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oligonucleotides and mini-sequencing products showed that the detection limit and
data robustness were greatly improved.

5.2 Methods and Materials
Oligonucleotides were purchased from MWG Biotech Inc.(High Point, NC,
USA).

3-Hydroxypicolinic

acid

(3-HPA),

diammonium

citrate,

and

NH4+

ion-exchange beads were obtained from Aldrich (Milwarkee, WI, USA). All samples
were used without further purification. The saturated 3-HPA matrix solution was
prepared in 50 mM diammonium citrate solution containing 25% (v/v) of acetonitrile.
Stock DNA solutions were prepared in water. The concentration of the DNA solution
was determined by UV absorption measurements. The DNA mixture solutions were
prepared prior to loading them on the sample tip.
All mass spectra were collected using OmniFlexTM MALDI-TOF mass
spectrometer (Bruker, Bilerica, MA, USA) operated in the linear, negative mode,
delayed extraction has been turned on. OmniFlexTM uses a 337-nm pulsed nitrogen
laser which has a duration of 3ns and a full power of 175μJ. Our experiment was
typically carried out at about 78% of full laser power with 600 ns delay extraction and
9.3kV ion focus voltage. This laser power was slightly higher than that used when
samples were prepared by conventional methods. Sampling rate is 2Hz. The sample
target was a 400μm, 6 x 6 anchorchipTM abtained from Brucker. If not specified,
otherwise, 2 μL of oligonucleotide solution were first deposited on the anchorchipTM,
followed by dispensing 0.1μL of the saturated 3-HPA matrix solution. All sample
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spots were searched manually to locate the “sweet” spots.

5.3 Results and Discussion
5.3.1 Sample Preparation
The first series of experiments was performed to determine the best sample
preparation conditions. The sample target used was a 400μm anchoring chip which is
coated with a thin film of Teflon-like hydrophobic material and carries a 400μm
hydrophilic center. The selection of anchoring chips over a pure hydrophobic center is
based on the observation that the sample solution tends to form a dried spot on the
hydrophilic surface, allowing the use of an automatic liquid handling system to
precisely deposit a small volume of matrix onto the top of a dried sample spot without
visualization.
The key to this procedure is to confine all deposited samples to the
hydrophilic surface. It was seen that the addition of a small amount of diammonium
citrate to the oligonucleotide solution could facilitate the shrinkage of a aqueous
solution on an anchoring chip and reduce the salt effects. The diammonium citrate
solution was normally treated with NH4+ ion-exchange beads before being added to
the oligonucleotide solution. In general, the sample solution contained 0.001M of
diammonium citrate if the oligonucleotide concentration was 0.01 μM or higher.
When lower concentration samples were analyzed, the amount of diammonium citrate
should accordingly be reduced. In this work, we manually dispensed both
oligonucleotide and matrix solutions to the sample target. Therefore, care was taken to
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deposit the sample solution onto the center of the anchoring spot. Otherwise, the
sample solution may not be confined to the hydrophilic center. In the same way, great
care was taken to deposit a small drop of the matrix solution onto the top of the
shrunk DNA spot. We found that the result was poorer if the matrix was not deposited
on the top of the sample spot. An automated liquid handling system should be used
when a large number of samples are prepared by this method, as this will eliminate
the potential human error during sample preparation.
We investigated the matrix concentration effect using the matrix solution at
three different concentrations. In all three cases, 0.1 μL of the 3-HPA solution was
loaded. We observed that the sample sizes created from these three solutions were
similar, but the more diluted the 3-HPA solution was, the thinner the 3-HPA film was
formed. The diluted solution tended to form a 3-HPA film containing many thin
needle-like threads. In contrast, the saturated solution produced many thin threads
surrounded by small crystals across the entire sample. Interestingly, it was the
saturated 3-HPA solution that gave the best results in terms of sensitivity,
homogeneity, and reproducibility. We also investigated the effect of CH3CN and
observed the similar results when the CH3CN concentration was 25-50%. Higher
concentration of the CH3CN will interfere with the shrinking process. The results
indicated that the careful selection of CH3CN combined with saturated 3-HPA yields
better matrix/sample co-crystals and more uniform samples (less gaps between crystal
threads), improving the sampling efficiency. Therefore, the saturated 3-HPA solution
prepared in 25% of CH3CN was used throughout this experiment. In general, the
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sample size formed by this procedure is about 0.4-0.6 mm.

5.3.2 Sensitivity and Homogeneity
Figure 5.1 shows typical MALDI-TOF mass spectra of equal molar
oligonucleotide mixtures containing either 16/17 or 24/25 mers. The samples were
prepared by loading 2 μL of the mixture solution, followed by the addition of 0.1 μL)
of the saturated 3-HPA solution to the dried oligonucleotide spot. The concentration of
each oligonucliotide mixture was ~0.01 μM (Figure 5.1(a) and 5.1(c)) and ~0.002 μM
(Figure 5.1(b) and 5.1(d)), respectively. As seen from Figure 5.1, all four
oligonucleotides were detectable at concentrations of 0.01 and 0.002 μM. However, at
0.01 μM, little efforts were needed to search for ‘sweet’ spots, while some searching
efforts were required if the concentration was reduced to 0.002μM. A similar
sensitivity was obtained with many other oligonucleotides including one 30 mer. It
should be noted that no attempt was made to determine the uppermost sensitivity of
this procedure as we were more interested in determining the lowest DNA
concentration at which we could produce homogenous and reproducible samples,
since these factors are equally important to genotyping of SNPs. Therefore, we
evaluated this new procedure at the oligonucleotide concentration of 0.01 μM or
higher in the rest of this work.
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Figrue 5.1 MALDI-TOF mass spectra of equal molar oligonucleotide mixtures of
16/17- and 24/25mers obtained at concentrations of 0.01µM ((a) and (c)) and
0.002µM ((b) and (d)).
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It was observed that the sample size could be further be further reduced, as
the sample size was dictated by the volume of matrix. At present, it is difficult for us
to load less than 0.1 μL of solutions with a standard syringe or pipetter. However, a
piezoelectric microdispenser can deposit as little as 10 nL of a solution on target
[Little et al., 1997; Miliotis et al., 2000]. It is anticipated that the use of a piezoelectric
microdispenser might further improve the sensitivity of this new procedure.
The ability of rapid screening of a large number of samples is essential to
high-throughput genotyping. A series of experiments with a mixture of 16- and 17
mers at 0.01 μM was conducted to evaluate the application of this procedure to a
high-throughput operation. First, we examined the signal duration on a given spot to
see whether a good spectrum can be generated just from a single targeted spot. Figure
5.2 displays three spectra collected from the first 30 shots, second 30 shots, and third
30 shots from the same targeted spot, respectively. In most of the cases, strong ion
signals were still observable even after 70 laser shots if the laser power was kept at
the level that was slightly higher than threshold. Importantly, it was seen that good
signal-to-noise (S/N) peaks could be robustly generated just from a single spot. The
good signal duration and quality allow acquisition of a good spectrum from one spot
instead of multiple spots, thereby avoiding the need to search for additional spots. It
should be noted that, in some cases, there were no oligonucleotide ion signals or
signals were much weaker during the first few laser shots. However, the signals
actually increased significantly after a few laser shots. This suggests that
oligonucleotides distributed from the top surface to the interior part of the 3-HPA film
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and that long signal duration may result from the formation of a thicker 3-HPA matrix
film.
The sample homogeneity was further examined by preparing samples in an
identical manner, followed by collecting one good spectrum from each of 36 wells. In
this experiment, we intended to determine how many sample spots should be searched
randomly to find a ‘sweet’ spot. An S/N ratio of 5 was used to accept or reject the
spectra. If the S/N ratio was equal to or better than 5, no more searching was
performed. Otherwise, more spots were searched until a good spectrum was collected.
In this experiment, the ‘sweet’ spots were searched manually. We found that all 36
samples produced the similar high-quality spectra and that the average number of the
spots searched was 2-3. For example, Figure 5.3 displays the typical spectra obtained
from sample targets 3, 7, 16, 24, 28 and 35, respectively. Moreover, we observed that
high-quality spectra could be produced across the entire sample. This result clearly
indicated that the samples prepared by this new procedure are highly homogenous and
therefore it is suitable for high-throughput DNA analysis.
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Figure 5.2 Typical MALDI-TOF mass spectra obtained from the first 30 shots,
second 30 shots, and third 30 shots.

Figure 5.3 Representative MALDI-TOF spectra obtained from 36 sample spots
prepared in an identical manner. The spectra shown were obtained from spots 3, 7, 16,
24, 28, and 35.
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5.3.4 Reproducibility and Quantitative Analysis
One other issue related to genotyping of SNPs is the determination of the
frequency of each of the two alleles when a pooling sample of many people is
analyzed. Therefore, we also evaluated this procedure for its applicability in
quantitative analysis of two oligonucleotides which are different by one base. The
objective of this evaluation was to determine how many people could potentially be
pooled together for an accurate determination of the allele frequencies. In this
experiment, six samples were prepared in an identical manner, and five spectra were
collected from five different positions from each of the six samples. The sample
mixture used contained 0.04 μM of 16- and 17 mers. Table 5.1 lists the signal
intensity ratios of the 16- and 17mer peaks from each of the 30 spectra. These peak
intensity ratios were calculated based on the peak aera including the area of the salt
adduct peaks. It was seen that, on average, only one out of 10 spots produced an
unusually large or small peak ratio. Based on this observation, we used the following
sampling procedure to improve the data reproducibility from spot to spot. All five
spectra collected from the same sample were compared with each other. If any spectra
produced a peak ratio larger or smaller than 30% of the average ratio, those spectra
were discarded and only the remaining spectra were used to calculate the average
peak ratio for that sample. Table 5.1 also lists the average peak ratios of each sample
after we discarded two peaks (point 2 of sample 1 and point 5 of sample 2) having
unusually large or small peak ratios. It was seen that the largest peak ratio difference
among the six samples could be reduced to a level of less than 10%. Therefore, we
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expect that when this method is used to measure the allele frequency of a pooling
sample of more than five individuals, the error of the resulting frequency will be
about 10%. However, if the pooling sample contains five individuals or less, this
method can yield the precise allele frequency, as the smallest genotype frequency
change is 33% from the 4/6 to 5/5 if the pooling sample contains five individuals.
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Table 5.1 Experimentally determined peak ratios and calculated average peak ratios
of 16/17mers. * SD = Standard Deviation
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5.3.5 Analysis of Mini-sequencing Products
This work was carried out with the primary aim of improving the overall
detection sensitivity of the MALDI-TOF based genotyping methods. Therefore, we
finally evaluated application of this method to the detection of mini-sequencing
products. Mini-sequencing is a short sequencing reaction which only extends the
sequencing primer by a few bases. The SNP site genotyped in this work was SNP888
[Martin et al., 2000]. Two people were genotyped. One is Homozygous, while the
other is C/T Heterozygous. In brief, genomic DNA was amplified by PCR, followed
by purification with a size-exclusion column. The purified PCR products were then
subjected to VSET mini-sequencing [Sun et al., 2000]. A sequencing primer is
annealed to the target alleles immediately upstream of the SNP site, which is extended
by one of the ddNTPs from one allele, then it is extended by the addition of one dNTP,
and then terminated by a ddNTP from another allele. As a result, two extension
products which differ by one base are produced from a heterozygous individual, while
only one extension product is yielded from homozygous person. 50 or 100 fmol of the
extension primer were used for mini-sequencing. A total of four identical
mini-sequencing reactions were prepared for each concentration. Mini-sequencing
products were subjected to purification with ZiptipTM (Millipore, MA, USA). The
Oligonucleotides were eluted from the tip with 1μL of an aqueous solution containing
20% of CH3CN. The mini-sequencing products were treated with the same tip three
times to improve the oligonucleotide recovery efficiency. Thereafter, all recovered
DNA solutions were combined and deposited on a sample well, followed by the
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addition of matrix.
Figure 5.4(a)-5.4(d) showed the results of genotyping of these two
individuals using 100 and 50 fmol of the extension primer, respectively. Figure 5.4(a)
and 5.4(b) were obtained from genotyping the C/T heterozygous individual, while
Figure 5.4(c) and 5.4(d) were obtained from genotyping the homozygous individual.
The peaks labeled P# (# =1 or 2) correspond to the extended primers. It was seen that
the genotypes of all samples were correctly identified. In general, the signal quality
and sample homogeneity from these mini-sequencing products were similar to those
of the samples produced with 20 fmol of pure oligonucleotides. This suggests that the
new procedure could indeed be used to analyze mini-sequencing products in a
sensitive and accurate manner. The sensitivity achieved with this new procedure is
about 10 times better than that achieved with currently used sample preparation
methods, and is comparable with the sensitivity of fluorescence-based detection.
Because of the lower amounts of extension primers used in mini-sequencing, less
PCR products and DNA polymerase are required for mini-sequencing.
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Figure 5.4 MALDI-TOF mass spectra obtained from genotyping two individuals ((a)
and (b) C/T heterozygous; (c) and (d) C homozygous) using 100 and 50 fmol of the
extension primers, respectively. The peaks labeled with * may be due to the products
arising from the impurityies present in the mini-sequencing primers
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5.4 Conclusions
A new procedure for preparing MALDI samples on a hydrophobic surface
was developed for the MALDI-TOF analysis of low-concentration oligonucleotides.
This new procedure was simple, robust, and superior to the conventional sample
preparation methods. It was shown that this procedure allowed the robust detection of
as low as 0.01μM of oligonucleotides ranging from 15- to 30 mer. Moreover, the
samples prepared by this procedure were more homogenous and therefore
substantially reduced the need to search for ‘sweet’ spots. The increased shot-to-shot
and

sample-to-sample

reproducibility

also

make

it

possible

to

perform

high-throughput and quantitative analyses of DNA. It was shown that this procedure
could reduce sample-to-sample peak ratio variation to the level of 10%, therefore
allowing the accurate determination of the allele frequency of a pooling sample of at
least five people. Importantly, we demonstrated that this procedure could improve the
overall detection sensitivity of the MALDI-TOF-based genotyping method by about
10-fold, evident by the robust detection of SNP888 using as little as 50 fmol of the
extension primer. This detection sensitivity is comparable with that of the
fluorescence-based detection method.
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CHAPTER VI
DETECTION OF MRS ALTERATIONS IN A LARGE BACKGROUND OF
NORMAL DNA FOR SCREENING OF MSI-H CANCERS

6.1 Introduction
High-frequency microsatellite instability (MSI-H) is a form of genetic
instability observed in virtually all tumors from tumors from patients with hereditary
nonpolyposis colorectal cancer (HNPCC) and in a subset of various sporadic cancers.
Its hallmark is extensive instability in simple repeat nucleotide sequences, including
mononucleotide repeat sequences (MRS) and microsatellites [Boland et al., 1998].
MSI-H is most common in colorectal, gastric, and endometrial cancers [Markowitz et
al., 1995; Halling et al., 1999; MacDonald et al., 2000; Alexander et al., 2001].
Colorectal cancer is the second deadliest cancer in the United States, and studies
identified that about 15% of colorectal cancers are MSI-H, suggesting an annual
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incidence in the United States of 20,000 to 26,000 MSI-H colorectal cancers each
year [Alexander et al., 2001].
Detection of colorectal cancer by the DNA analysis from stools is a
promising screening method [Ahlquist et al., 2000 and 2002; Dong et al., 2001;
Traverso et al., 2002a,b]. MRS markers are excellent indicators of MSI-H [Myeroff et
al., 1995; Hoang et al., 1997; Grady et al., 1998; Zhou et al., 1998; Lacopetta et al.,
1999; Loukola et al., 1999; Jin et al., 2001; Loukola et al., 2001]. For example,
BAT26 alterations were found in > 90% of MSI-H colon tumors, and 85% of MSI-H
colon cancers harbor a mutation in transforming growth factor-β-RII (A)10
(TGF-βRII (A)10) [Myeroff et al., 1995; Hoang et al., 1997; Zhou et al., 1998;
Loukola et al., 2001]. Studies show that alterations of these markers are not present in
normal tissues, suggesting that they are tumor specific [Grady et al., 1998; Lacopetta
et al., 1999; Loukola et al., 1999; Jin et al., 2001]. Stools contain only a small
percentage of mutated cells. Thus, molecular assays need to be highly sensitive such
that altered DNA can be readily detected in a large background of wild-type DNA.
Highly sensitive PCR-based methods are available for the point mutation detection
[Orum et al., 1993; Jacobson et al., 1994; Lehman et al., 1996; Peter et al., 1997; Zirvi
et al., 1999; Sun et al., 2002], but they are not suited for MRS analysis, as PCR itself
can produce substantial slippage errors when a locus containing MRS is amplified. In
other words, PCR can artificially yield mutant alleles even in the absence of mutant
DNA, leading to false-positives.
Ahlquist et al. reported on the use of a modified primer extension method for
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the detection of BAT26 mutations in stool [Ahlquist et al., 2000 and 2002; Dong et al.,
2001]. However, primer extension methods may not work well for the detection of
mutations in short MRS markers, such as TGF-β-RII (A)10, because polymerase
slippage PCR products generated from the wild-type DNA can substantially overlap
with the common (A)9 mutant. Recently, Vogelstein et al. developed an elegant digital
PCR method [Vogelstein et al., 1999] and successfully employed this approach to
detect mutant BAT26 alleles in fecal DNA [Traverso et al., 2002]. Digital PCR is
sensitive, but the method requires analysis of a large number of subdivided samples
each containing a single DNA molecule to screen each patient.
We herein report an alternative detection strategy referred as probe clampling
primer extension-PCR (PCPE-PCR) for the detection of MRS alternations in a large
background of wild-type DNA. We demonstrated that PCPE-PCR can detect both
mutated BAT26 and TGF-β-RII (A)10 markers in the presence of 500-fold excess of
normal DNA, and that as few as three copies of mutant DNA could be detected.

6.2 Methods and Materials
Normal DNA was purchased from Sigma (St. Louis, MO). Mutant
TGF-β-RII (A)10 DNA was extracted from cell line of HCL116, and mutant BAT26
DNA was collected from cell line of HEC1A. The low-abundance mutant DNA
samples were created by mixing mutant DNA with normal DNA. The abundance and
number of mutant DNA in the created samples were estimated based on the number of
mutant DNA in the original samples and dilution factors. The stool DNA samples
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were extracted from stools of MSI-H colorectal cancer patients [Traverso et al., 2002].
In this work, a peptide nucleic acid probe of 5’-GGCTTTTTTTTTTCCT-3’ (Applied
Biosystems, Foster City, CA) was used for TGF-β RII (A)10 assay, and an oligo probe
(5’-GGTAAAAAAAAAAAAAAAAAAAAAAAAAAGGG-3’ ) was used for BAT26
assay. The oligo probe was phosphorothioted at the first five positions of 5’ and 3’
ends to minimize the probe cleavage by DNA polymerases and was also 3’-end
phosphorylated to prevent the probe itself from undergoing primer extension.
For TGF-β RII (A)10, PCPE was carried out in 25μL using 3 μmol/L of the
peptide

nucleic

acid

probe,

0.01μmol/L

(5’-Biotin-TGCACTCATCAGAGCTACAGG-3’),

of

the

extension

0.1mmol/L

of

primer
each

deoxynucleotide triphosphates, 2mmol/L of MgCl2, 1x AmpliTaq Gold PCR buffer,
and 0.5 unit of AmpliTaq Gold DNA polymerase (Applied Biosystems). After
denaturation at 95℃ for 10 minutes, PCPE was done for 25 to 50 cycles consisting of
30 seconds at 95℃, 120 seconds at 58℃, 60 seconds at 54℃, and 60 seconds at 72℃,
with a final extension of 5 minutes at 72℃. After PCPE, the formed single-strand
DNA fragments were captured using streptavidin-coated magnetic beads (Dynal
Biotech, Lake Success, NY). Twentyfive microliters of extension products were
mixed with equal volume magnetic beads in B&W buffer (10mmol/L Tris-HCl (pH
7.5), 1mmol/L EDTA, 2.0mol/L NaCl ), and incubated at room temperature for 1 to 3
hours. Thereafter, the supernatants were removed followed by washing the beads with
200 μL of 0.1mol/L NaOH for 5 minutes, and twice by water.
A similar procedure was used for BAT26 except for that PCPE was done in
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25 to 50 cycles consisting of 30 seconds at 95℃, 120 seconds at 68℃, 60 seconds at
62℃, and 60 seconds at 72℃, with a final extension of 5 minutes at 72℃. The
extension primer is 5’-Biotin-TGCAGTTTCATCACTGTCTGC-3’.
The purified beads containing the single-strand DNA fragments served as
templates of fluorescence-based PCR. The PCR mixture included 1x PCR buffer,
0.2mmol/L of each deoxynucleotide triphosphates, 2mmol/L MgCl2, 0.1 μmol/L of
the forward and reverse primers, and 0.5 unit of TaqGold DNA polymerase,
respectively. After denaturation at 95℃ for 10 minutes, PCR (25μL) was done for 42
cycles consisting of 30 seconds at 95℃, 30 seconds at 54℃, and 30 seconds at 72℃,
with a final extension of 5 minutes at 72℃ for TGF-β RII (A)10 and BAT26. The
fluorescence-labeled PCR products were size analyzed using a CEQ8000 sequencer
(Beckman Coulter, Fullerton California). The forward and reverse primers used were
5’-GAAGATGCTTCTCCAA-3’ and 5’-dye(D4)-ATCAGAGCTACAGGAACAC-3’
for

TGF-β-RII

(A)10,

5’-dye(D4)-ATTGGATATTGCAGCAGTC-3’

and

5’-AACCAATCAACATTTTTAACCC-3’ for BAT 26, respectively.
Fecal DNA samples from individuals having MSI-H colon cancers were the
kind gift of Dr. Bert Vogelstein (John Hopkins University) and corresponded to
samples previously employed in studies published by Dr. Vogelstein’s laboratory.

6.3 Results and Discussion
6.3.1 Principle of PCPE-PCR
A PCPE-PCR assay consists of five steps. First, DNA is extracted from a
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clinical sample, such as stools. Second, the DNA samples containing both mutant and
wild-type alleles are subject to PCPE that preferentially produces extension products
of mutant DNA. Third, the extension products are extracted, leading to enrichment of
mutant DNA. Fourth, PCR is done using the extracted extension products as templates.
Finally, PCR products are analyzed using DNA fragment analysis or other methods to
reveal the mutations. Figure 6.1 shows a schematic representation of detecting mutant
DNA (A9) in a large background of normal DNA (A)10 by PCPE-PCR.
The second and third steps are key to PCPE-PCR. As shown in Figure 6.1,
the PCPE system has an extension primer and a blocking probe, both of which are
complementary to the same strand of the wild-type sequence. The blocking probe is
complementary to a wild-type sequence containing MRS and designed in such a way
that probe-DNA duplexes are more stable than extension primer-DNA duplexes when
DNA is wild-type but less stable than extension primer-DNA duplexes if DNA is
mutated. As a result, this blocking probe can tightly bond to wild-type DNA,
preventing read-through by polymerases (elongation arrest); thus, shorter extension
products that do not contain the MRS sequence are formed (note that they will not be
amplified by the following PCR as one of the PCR primers will not cover them). In
contrast, when DNA is mutated, this blocking probe would no longer bind to the
targeted mutation site; thereby, primer elongation is initiated by polymerases, and
long extension products containing the altered MRS sequence are formed. In this
method, we use solid-phase extraction to extract the extension products. A biotin is
incorporated to the extension primer; therefore, the formed extension products are
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consequently biotinylated as well. The extension products are isolated using a
biotin-streptavidin affinity extraction procedure, leading to enrichment of mutant
DNA. Thereafter, we use the extracted extension products as PCR templates, and the
mutation is revealed by analyzing the PCR products.
In this study, we used the TGF-β-RII (A)10 and BAT26 markers as examples
to show the detection of mutations in both short and long MRS markers by this new
technology, respectively.
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Figure 6.1 Schematic illustration of the PCPE-PCR principle of detecting mutant
DNA (A9) in the presence of a large background of normal DNA (A10).
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6.3.2 Detection of Mutations in TGF-β RII (A) 10
We first used PCPE-PCR to detect mutations of short MRS marker, which
contain 12 or less repeats, and they are often altered by one or two bases. Because of
PCR slippage, it can be challenging to detect these mutations in the presence of
excessive wild-type alleles. For example, 10% to 30% of the PCR products amplified
from the normal TGF-β-RII (A)10 allele can be shortened A9 alleles, making it
challenging for

conventional methods to detect the legitimate presence of the mutant

A9 allele if the abundance of mutant DNA is low. However, the detection of this
marker was readily achieved by PCPE-PCR.
Figure 6.2A shows the PCR product distribution obtained using primer
extension but without blocking probe. The sample contained only wild-type DNA. It
was seen that this distribution was identical to that generated from PCR without
primer extension, establishing the fact that the sequence of the DNA molecule
produced from primer extension truly reflects that of genomic DNA. The A9 peak
seen in Figure 6.2A was due to PCR slippage, and its intensity was generally <50%
of the A10 intensity. Because of this fact, we can use the peak intensity ratio of A9 to
A10 to determine whether mutant DNA is present. It was found that a ratio of 0.8 is a
good threshold to robustly distinguish the legitimate presence of the A9 allele from
the artificial production of this allele by PCR slippage. In other words, we called the
legitimate presence of the mutant A9 allele in the sample if the ratio is 0.8. Otherwise,
the absence of mutant DNA would be called.
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Figure 6.2 TGF-β-RII (A)10 spectra obtained from different conditions. It is noted
that: (a) PE-PCR denotes the use of primer extension (without the blocking probe)
followed by PCR; (b) the percentage indicates the abundance of mutant DNA in the
sample; (c) the peak A9 corresponds to mutant DNA, whereas the peak A10
corresponds to wild-type DNA.
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Figure 6.2B shows the result of detecting 1% (0.5 ng) of mutant DNA in 50
ng of normal DNA without the blocking probe, where no mutant DNA was observed.
In contrast, Figure 6.2C displays the result obtained from the same sample but with
the blocking probe, where the A9 peak became stronger than the A10 peak, indicating
the legitimate presence of mutant DNA in the sample assayed. Figure 6.2D displays
the result of detecting 0.1 ng (0.2%) of mutant DNA in 50 ng of normal DNA, where
the A9 peak was still stronger, establishing that PCPE-PCR could detect 0.2% of
mutant TGF-h-RII (A)10. The amount of human DNA extracted from a clinical
specimen may vary from patient to patient; thus, the assay must have a good dynamic
range. Figure 6.2E displays the detection of mutant DNA (0.2%) in the presence of 1
µg of normal DNA, indicating that PCPE-PCR works well in a large dynamic range.
It should be noted that the specificity of this assay is good as shown by assaying pure
wild-type DNA (Figure 6.2F), where the A9 peak was <50% of the A10 peak,
correctly indicating the absence of mutant DNA. .

6.3.3 Detection of Mutations in BAT26
We next used PCPE-PCR to detect mutations in large MRS markers. These
makers generally contain 20 repeats or more and typically contract by multiple bases.
BAT26, one of the most wildly used markers for MSI-H colon cancer, was examined.
BAT26 typically contracts by 10 bases or more in MSI-H colorectal cancer but
contracts less in adenoma. The data shown here were based on the detection of mutant
BAT26 from cell line HEC1A, in which one allele contains about 14As (large
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deletion), whereas another has 20As (small deletion). The use of this mutant cell line
allowed us to evaluate the performance of PCPE-PCR in the detection of both small
and large deletions under the same assaying condition. Figure 6.3A and 6.3B shows
the PCR product distribution of both pure normal and mutant BAT26 DNA,
respectively. The numbers shown in these spectra specify the size of the
corresponding PCR products. The peaks clustering around the positions of 86, 80, and
74 corresponded to the PCR products arising from wild-type BAT26, small deletion in
BAT26, and large deletion in BAT26, respectively. The formation of multiple peaks
resulted from PCR slippage. As seen from Figure 6.3A, when there was no mutant
DNA, the PCR products of wild-type DNA cluster around peak 86, and the peak
intensity of smaller PCR products generally decrease with a decrease in DNA size.
For example, peak 80 is weaker than peak 81. However, when mutant DNA was
present, the PCR product distribution changed substantially as shown in Figure 6.3B.
In general, the PCR products of BAT26 with large deletion do not substantially
overlap with those of normal DNA, allowing the determination of mutant DNA based
on the DNA fragment size. For example, the appearance of peaks around position 74
is indicative of large deletion in BAT26. Although PCR products of BAT26 with small
deletion do overlap with those of wild-type DNA, the peak intensity pattern becomes
altered due to overlapping. For example, peak 79 is stronger than peak 81 in Figure
3B. Thus, we were able to determine whether small deletion in BAT26 was
legitimately present based on the resulting changes in the peak intensity pattern.
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Figure 6.3 BAT26 spectra obtained from different conditions and samples. It is noted
that: (a) PE-PCR denotes the use of primer extension (without the blocking probe)
followed by PCR; (b) the percentage indicates the abundance of mutant DNA in the
sample; and (c) the numbers of 86, 80, 79, and 74 specify the size of the
corresponding PCR products.
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Figure 6.3C shows the detection of 1% (0.5 ng) of mutant DNA in 50 ng of
wild-type DNA without the blocking probe, where no mutant DNA was observed.
Figure 3D displays the result obtained form the same sample but with the blocking
probe, where new peaks appeared around the peak position of 74, indicating the
presence of large deletion in BAT26. In addition, peaks 79 and 80 became stronger
than peak 81, suggesting the presence of small deletion in BAT26. Figure 6.3E
displays the result of detecting 0.1 ng of mutant DNA (0.2%) in 50 ng of normal DNA,
where the peaks clustering around 74 were seen, revealing the presence of large
deletion in BAT26. Moreover, peak 79 was higher than peak 81, indicating the
presence of small deletion in BAT26. Figure 6.3F was obtained using pure wild-type
DNA, where neither new peaks nor a change in the peak intensity pattern were
observed, indicating the absence of mutant DNA. It is noted that the above
experiments were repeated at least twice, and the consistent results were obtained.
Several studies established that the abundance of mutant DNA in stools was
generally >0.5% [Dong et al., 2001; Traverso et al., 2002a,b]; thus, an assay with such
a sensitivity should be adequate to detect mutant BAT26 from stools [Traverso et al.,
2002a,b]. Although the BAT26 assay is generally more sensitive to detecting large
deletion in BAT 26, it is capable of detecting 0.2% of mutant BAT26 that was deleted
by six bases, suggesting that the PCPE-PCR–based BAT26 assay could detect both
small and large deletion in BAT26 in a sensitive manner. This feature is important to
screening as the size of deletion in BAT26 varies among patients.
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Figure 6.4 Fragment analysis spectrum obtained from the PCPE-PCR analysis of
three copies of both large deletion and small deletion BAT26 in the presence of 600
copies wild-type DNA.
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Because mutant DNA extracted from stools could be scanty [Dong et al.,
2001; Traverso et al., 2002a,b], we also determined the lowest copy of the mutant
BAT26 molecules that could be detected in the presence of a 200-fold excessive
amount of wild-type DNA. As seen from Figure 6.4, three copies of both 12- and
6-base deleted BAT26 were detected in the presence of 600 copies of normal DNA
using our BAT26 assay. It was reported that at least 4,000 copies of human DNA
could be extracted from 10 g of stools, yielding at least 20 copies of mutant DNA
[Dong et al., 2001; Traverso et al., 2002a,b]. Thus, the BAT26 assay is sufficiently
sensitive for fecal DNA testing.

6.3.4 Detection of Mutations from Fecal DNA
We finally tested the BAT26 assay in a set of six fecal DNA samples
extracted from stool samples collected from MSI-H colorectal cancer patients to
determine whether this assay can detect MSI-H colorectal tumors. Stool DNA was
extracted and purified as described previously [Traverso et al., 2002]. Because the
samples were originally extracted for digital PCR, the total number of human DNA
molecules in them is low. Figure 6.5 shows the result of detecting the BAT26
mutations from one of the stool DNA samples using PCPE-PCR, where the total
amount of stool DNA used was about 120 copies. The peaks clustering around the
peak position 72 indicated the presence of mutated BAT26, thus revealing that this
patient has an MSI-H colorectal tumor. Mutated BAT26 molecules were similarly
successfully detected from three of the other assayed fecal DNA samples. However,
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two of the six fecal DNA samples from MSI-H patients tested negative for BAT-26
because of failure of observing PCR products. During the course of this work, we
found that the assay would become less robust when mutant DNA molecules were
less than three copies. This is because robust isolation of extension products became
challenging if fewer biotinylated molecules were formed. Because the total number of
human DNA in the samples are 120 copies, we suspect that in these two negative
samples, the copy number of mutant DNA may be <3, which is the minimum level
required for PCPE-PCR to detect the mutated BAT26 molecules.
The test is clearly very sensitive; however, the specificity has yet to be
completely determined with fecal DNA samples and will need to be further studied in
a large number of samples from patients.
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Figure 6.5 Fragment analysis spectrum obtained from the PCPE-PCR analysis of the
BAT26 mutation in a stool DNA sample collected from a MSI-H colorectal cancer
patient. It is noted that the peaks around 72 correspond to mutated BAT26, whereas
the peaks around 86 correspond to wild-type DNA.
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6.4 Conclusion
PCPE-PCR offers several unique features. First, PCPE-PCR is sensitive.
Second, the same PCPE-PCR assay can be used to detect both large and small
deletions. Third, the PCPE-PCR assay uses primer extension as pre-amplification to
increase template copies, allowing the detection of low copies of mutant DNA. This
feature is particularly useful in analysis of fecal-derived DNA, where mutant DNA
may be scarce. Finally, PCPE-PCR is simple and amendable to a cost-effective and
high-throughput operation.
Clearly, the primary application of the PCPE-PCR assay is for noninvasive
screening of MSI-H cancers. In the case of colorectal cancer, a combination of
sigmoidoscopy and stool analysis has been suggested to be a potentially cost-effective
alternative to colonoscopy [Traverso et al., 2002]. Sigmoidoscopy inspects the distal
colon, whereas PCPE-PCR detects MSI-H tumors, which often occur in the proximal
colon. Hence, PCPE-PCR can be a part of a group of methods for screening of
colorectal cancers. It should be noted that the PCPE-PCR strategy reported here is a
general strategy and thus can also be used to design assays for the detection of other
important MRS markers, including BAT25 and short MRS in BAX [Lacopetta et al.,
1999]. If this method is used to detect a marker such as BAT 26, which is
polymorphic, it is necessary to test germ line DNA to distinguish the legitimate
mutations from polymorphism. In addition, PCPE-PCR can detect other DNA
mutations. In the case of point mutations, our preliminary work indicated that
PCPE-PCR could detect p53 mutations in a large background of normal DNA. Hence,
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PCPE-PCR could potentially serve as a generally applicable method for the detection
of various DNA alterations in a large background of normal DNA.
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